

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number  
**WO 01/12127 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number: PCT/US00/22882
- (22) International Filing Date: 17 August 2000 (17.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- |            |                               |    |
|------------|-------------------------------|----|
| 09/378,567 | 19 August 1999 (19.08.1999)   | US |
| 09/459,813 | 13 December 1999 (13.12.1999) | US |
| 09/492,935 | 27 January 2000 (27.01.2000)  | US |
| 09/559,248 | 26 April 2000 (26.04.2000)    | US |
- (71) Applicant: **STEM CELL PHARMACEUTICALS, INC.** [US/US]; 562 First Avenue South, Suite 700, Seattle, WA 98104 (US).
- (72) Inventors: **TWARDZIK, Daniel, R.**; 10195 Southbeach Drive, Bainbridge Island, WA 98110 (US). **PERNET, Andre**; 1221 S. Estate Lane, Lake Forest, IL 60045 (US). **FELKER, Thomas, S.**; 11344 S.W. Mc Cormick Place, Vashon, WA 98070 (US). **PASKELL, Stefan**; 6075 N.E. Tolo Road, Bainbridge Island, WA 98110 (US).
- (74) Agent: **HAILE, Lisa, A.**; Gray Cary Ware & Friedenrich LLP, 4365 Executive Drive, Suite 1600, San Diego, CA 92121-2189 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: TGF- $\alpha$  POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR

(57) Abstract: Disclosed are TGF- $\alpha$  polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include *ex vivo* and *in vivo* applications.



**WO 01/12127 A2**

## **TGF- $\alpha$ POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR**

### **FIELD OF THE INVENTION**

The present invention relates generally the field of tissue repair and more  
5 specifically to the use of transforming growth factor alpha (TGF- $\alpha$ ) polypeptide,  
fragments and mimetics for stimulating stem cells proliferation, migration and  
differentiation.

### **BACKGROUND**

Stem cells and tissue precursor cells play important roles in the development,  
10 regeneration and repair of organisms and particularly tissue and organs. Stimulation  
of tissue regeneration and repair can provide needed benefit to organisms suffering  
from injury, disorders or diseases which impair physiological functions increasing  
mortality and morbidity. For example, there are several disease treatments that  
could significantly benefit by having cells regenerate after injury or lesion formation.  
15 For example, in some instances, a particular treatment for a disease often  
detrimentally affects the subject being treated. One such example, is the  
administration of chemotherapeutic agents to subjects, which results in destruction of  
healthy cells, for example, cells of the gastrointestinal tract. Such chemotherapeutic  
agents include carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol),  
20 Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methoxetrate (Mexate),  
taxol, CPT111, etoposide, and plicamycin (Mithracin) which are known for their  
direct stomatotoxic potential (Sonis, 1993, "Oral Complications in Cancer Therapy,"  
In: Principles and Practice of Oncology, pp. 2385-2394, DeVitta *et al.*, Eds., J. B.  
Lippincott, Philadelphia) and hence incidence of mucositis.

Oral mucositis is an example of a disorder resulting from the cytotoxic effects of chemotherapy and/or radiotherapy on the rapidly dividing epithelial cells of the oropharyngeal mucosa, and is exacerbated by infection with both endogenous oral  
5 flora and opportunistic bacterial and fungal pathogens. Complications related to oral mucositis vary in the different patient populations affected, but typically include pain, poor oral intake with consequent dehydration and weight loss, and systemic infection with organisms originating in the oral cavity. The pain associated with oral mucositis may be severe requiring narcotic analgesics, and the difficulty in eating can result in  
10 patients receiving total parenteral nutrition.

Accordingly, adult cell renewal via the differentiation of immature cells can help to alleviate the problems associated with tissue and cellular damage. For example, stimulating renewal of blood and lymphoid cell types by stimulating  
15 developmentally immature precursors (hematopoietic stem and progenitor cells) can assist in treating disorders associated with blood or lymphatic cell depletion.

While the hematopoietic system is the best understood self-renewing adult cellular system, it is believed that most, perhaps all, adult organs harbor precursor  
20 cells that under the right circumstances, can be triggered to replenish the adult tissue. For example, the pluripotentiality of neural crest cells and tissues of the adult gut contain immature precursors which replenish the differentiated tissue. The liver has the capacity to regenerate because it contains hepatic immature precursors. In addition, various epithelial cells, including cells of the skin renew due to proliferation  
25 and differentiation of stem cells. Through the mesengenic process, most mesodermal derivatives are continuously replenished by the differentiation of precursors. Such repair recapitulates the embryonic lineages and entails differentiation paths which involve pluripotent progenitor cells.

30 Mesenchymal progenitor cells are pluripotent cells that respond to specific signals and adopt specific lineages. For example, in response to bone morphogenic

factors, mesenchymal progenitor cells adopt a bone forming lineage. For example, in response to injury, mesodermal progenitor cells can migrate to the appropriate site, multiply and react to local differentiation factors, consequently being induced down a distinct differentiation path. It has been suggested that the reason that limited tissue repair is observed in adults is because there are too few progenitor cells which can adopt specific differentiation lineages. It is clear that if such progenitor cells could be expanded tissue repair could be occur much more efficiently. In addition, an expanded pool of stem and progenitor cells, as well as non-terminally differentiated cells supplying a desired differentiation phenotype, would be of great value in transplantation and gene therapy as well as a myriad of therapeutic regimens.

### SUMMARY OF THE INVENTION

The invention provides methods and compositions useful for expanding precursor cell and stem cells, including adult stem cell populations *in vitro*, *in vivo*, or *ex vivo* or a combination thereof. The methods and compositions are useful in treating a number of diseases, disorders or injuries by inducing the expansion, migration and differentiation of precursor cells, stem cells or adult stem cells.

In one embodiment, the invention provides a method for protection of a tissue or an organ from damage by a cytotoxic agent or other injury causing agent or activity. The method includes administering an effective amount of a TGF- $\alpha$  polypeptide (SEQ ID NO:1), a TGF- $\alpha$  related polypeptide, a TGF- $\alpha$ 57 polypeptide (SEQ ID NO:3), a functional fragment thereof or a mimetic thereof to the tissue or organ prior to, simultaneously with or subsequent to contacting the tissue or organ with the cytotoxic agent or the injury causing agent or activity. Tissues include gastrointestinal tissue, urogenital tissue, musculoskeletal tissue, nerve tissue, or cardiovascular tissue, for example.

In another embodiment, the invention provides a method for treating, regenerating or repairing a tissue of a subject *in vivo*. The method includes contacting a tissue with a TGF-  $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a fragment or a

mimetic thereof prior to, contemporaneously with, or subsequent to a tissue injury in an amount effective to induce stem cell or precursor cell proliferation, migration, or differentiation at the site of injury thereby treating, regenerating or repairing the tissue. Contacting may be as a continuous infusion or by a bolus or single  
5 administration, for example.

In yet another embodiment, the invention provides a method for treating or preventing mucositis of the gastrointestinal tract in a subject. The method includes administering a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a TGF- $\alpha$ 57  
10 polypeptide, a fragment thereof, or a mimetic thereof in an amount effective to treat, inhibit or prevent gastrointestinal mucositis in the subject.

In another embodiment, the invention provides a method for expansion of a precursor cell, stem cell, or adult stem cell by recombinantly expressing within the  
15 cell an amount of a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a functional fragment thereof, or a mimetic thereof effective to induce proliferation of the cell; and culturing the cells under conditions such that the cell proliferates.

In another embodiment, the invention provides a method for expansion of a  
20 hematopoietic precursor cell, an epithelial precursor cell, or a liver precursor cell, for example. The method includes recombinantly expressing within the cell an amount of a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a functional fragment thereof, or a mimetic thereof effective to induce proliferation of the cells; and culturing the cell under conditions such that the cell proliferates. Preferably, the precursor cell is a  
25 human cell.

In another embodiment, the invention provides a method for promoting mammalian neuronal cell growth by contacting a mammalian neuron *in vitro* with a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a functional fragment thereof, or a  
30 mimetic thereof effective to induce proliferation of the cells; and culturing the cells under conditions such that the cell proliferates.

In yet another embodiment, the invention provides a method for expanding stem cells *ex vivo*. The method includes culturing stem cells from a subject and contacting the stem cell culture with a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a functional fragment thereof, or a mimetic thereof in an amount  
5 necessary to augment stem cell growth.

In another embodiment, the present invention provides a method for treating Type I or Type II diabetes by expanding a subject's population of insulin-producing  
10 cells. The method includes administering an effective amount of a TGF- $\alpha$  polypeptide (SEQ ID NO:1), a TGF- $\alpha$  related polypeptide, a TGF- $\alpha$ 57 polypeptide (SEQ ID NO:3), a fragment thereof, or a mimetic thereof in an amount effective to expand the population of insulin-producing cells.

Also provided is a method for treating AIDS and HIV infection by increasing  
15 a subject's population of CD4+ T cells. The method includes administering an effective amount of a TGF- $\alpha$  polypeptide (SEQ ID NO:1), a TGF- $\alpha$  related polypeptide, a TGF- $\alpha$ 57 polypeptide (SEQ ID NO:3), a fragment thereof, or a mimetic thereof.

20

#### BRIEF DESCRIPTION OF THE FIGURE

**Figure 1** shows the structure of rat TGF- $\alpha$  polypeptide and its 50 amino acids arranged into three loops (SEQ ID NO:2). The human TGF- $\alpha$  sequence is provided in  
25 SEQ ID NO:1 with a similar tertiary structure and a close sequence homology.

25

**Figure 2** shows a graph comparing TGF- $\alpha$  biological activity of the three loop peptide regions of TGF $\alpha$  (see Figure 1) wherein Loop A is amino acids 1-21 (starting at the N terminus), Loop B is amino acids 16 to 32 and Loop C is amino acids 33 to 50. Only Loop C showed significant TGF- $\alpha$  activity as determined by cell  
30 proliferation and in a dose response fashion.

**Figure 3** shows a graph of mouse spleen weights that were treated with Cis Platinum (CP) at either 5 mg/kg or 10 mg/kg and with TGF- $\alpha$  at concentrations of 10  $\mu$ g/kg or 50  $\mu$ g/kg. These data show that TGF $\alpha$  treatment caused a return to normal spleen weights despite CP treatment that reduced spleen weights significantly.

**Figure 4** depicts a summary of histological data that measured average crypt height of the three groups of mice. TGF- $\alpha$ 57 treatment (50  $\mu$ g/kg) was able to more-than-restore crypt height loss from CP treatment.

**Figure 5** shows a graph depicting the effects of cisplatinum-alone, cisplatinum and a TGF- $\alpha$  polypeptide, and a TGF- $\alpha$  alone on weight loss of mice.

**Figure 6** shows weight loss in mice following cisplatin administration with and without concurrent TGF- $\alpha$  treatment. The graph shows (from left to right) the proportion of weight-loss in the presence of PBS alone, TGF- $\alpha$  alone, cisplatin alone, and cisplatin+TGF- $\alpha$ .

## DETAILED DESCRIPTION OF THE INVENTION

The present invention also provides compositions containing TGF- $\alpha$  polypeptides, a TGF- $\alpha$  related polypeptide, mimetic, or a fragment having TGF- $\alpha$  activity as well as polynucleotides encoding the polypeptides and fragments thereof. In addition, the invention provides methods of using the polypeptides and polynucleotides of the invention for treating or preventing a number of diseases and disorders as well as stimulating stem cell proliferation.

TGF- $\alpha$  is a member of the epidermal growth factor (EGF) family and interacts with one or more receptors in the EGF-family of receptors. TGF- $\alpha$  stimulates the receptor's endogenous tyrosine kinase activity which results in activating various cellular functions, such as stimulating a mitogenic or migration response in a wide variety of cell types. TGF- $\alpha$  and EGF mRNAs reach their highest levels and relative

abundance (compared to total RNA) in the early postnatal period and decrease thereafter, suggesting a role in embryonic development. From a histological perspective, TGF- $\alpha$  is found in numerous cell types and tissues throughout the body. The active form of TGF- $\alpha$  is derived from a larger 30-35 kD precursor and contains  
5 50 amino acids. Human TGF- $\alpha$  shares only a 30% structural homology with the 53-amino acid form of EGF, but includes conservation and spacing of all six cysteine residues. TGF- $\alpha$  is highly conserved among species. For example, the rat and human polypeptides share about 90% homology compared to a 70% homology as between the rat and human EGF polypeptide. The amino acid sequence of human TGF- $\alpha$  is  
10 shown in SEQ ID NO:1. TGF- $\alpha$  shares cysteine disulfide bond structures with a family of TGF- $\alpha$  related proteins including vaccinia growth factor, amphiregulin precursor, betacellulin precursor, heparin binding EGF-like growth factor, epiregulin (rodents), HUS 19878, myxomavirus growth factor (MGF), Shope fibroma virus growth factor (SFGE), and schwannoma derived growth factor. Such TGF- $\alpha$  related  
15 polypeptides are also useful in the methods of the invention.

TGF- $\alpha$  is an acid and heat stable polypeptide of about 5.6 kDa molecular weight. It is synthesized as a larger 30-35 kDa molecular weight glycosylated and membrane-bound precursor protein wherein the soluble 5.6 kDa active form is  
20 released following specific cleavage by an elastase-like protease. TGF- $\alpha$  binds with high affinity in the nanomolar range and induces autophosphorylation of one or more members of EGF receptor family (*e.g.*, ErbB1 through 4 or receptors that bind a neuregulin ligand) to transduce subsequent signal pathways with the EGF receptors. TGF- $\alpha$  is 50 amino acids in length and has three disulfide bonds to form its tertiary  
25 configuration. TGF- $\alpha$  is stored in precursor form in alpha granules of some secretory cells.

Human TGF- $\alpha$  is a polypeptide of 50 amino acids. The corresponding rat sequence is shown in Figure 1. The human or rat TGF- $\alpha$  polypeptide can be divided  
30 roughly into three loop regions corresponding roughly (starting at the N terminus) to



amino acids 1-21, to amino acids 16-32, and to amino acids 33-50. As discussed more fully below, the invention provides functional fragments of TGF- $\alpha$  that retain TGF- $\alpha$  biological activity. "Functional fragment" as used herein means a TGF- $\alpha$  peptide that is a fragment or a modified fragment of a full length TGF- $\alpha$  polypeptide or related polypeptide so long as the fragment retains some TGF- $\alpha$  related biological activity (*e.g.*, interacts with an EGF family receptor, stimulates proliferation, migration, and/or differentiation of stem cells, or is useful for treating or preventing cachexia). Other biological activities associated with the polypeptides of the invention include, for example, mitogenic effects on stem cells and their more differentiated progeny of various tissues (*e.g.*, epithelial stem cells, hematopoietic stem cells, neural stem cells, liver stem cells, keratinocyte stem cells, and pancreatic derived stem cells).

The invention provides methods of using TGF- $\alpha$ , related polypeptides and peptide fragments thereof as disclosed herein to stimulate stem cell proliferation, stimulate hematopoiesis in subjects undergoing cytotoxic cancer chemotherapy, to act as a cytoprotective agents and in treatments for subjects at risk of or having weight-loss disorders associated with cancer cytotoxic therapy. Such disorders include gastrointestinal (GI) mucositis, which can result from cytotoxic therapy. While not wanting to be bound to a particular theory, it is believed TGF- $\alpha$  may alleviate GI mucositis, in part, through its mitogenic effect on GI epithelial stem cells.

The present invention provides methods for the expansion of non-terminally differentiated cells ("precursor cells") by contacting a precursor cell or a population of precursor cells with a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, mimetic, or a fragment having TGF- $\alpha$  activity, and stimulating the precursor cells to proliferate, migrate and/or differentiate. In one embodiment, precursor cells are stimulated to proliferate while differentiation is inhibited. As used herein, a "precursor cell" includes any non-terminally differentiated cell. Precursor cells are typically stem cells or progenitor cells, including adult stem cells or adult progenitor cells. The invention is also directed to methods for the expansion of precursor cells by contacting the cells with

a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, mimetic, or a fragment having TGF- $\alpha$  activity, such that the precursor cells are stimulated to proliferate, migrate and/or differentiate or differentiation of the precursor cell is inhibited without affecting the mitotic activity of the cell. Further, the precursor cells can be isolated from a cell  
5 population, if desired, before or after contacting with a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, mimetic, or a fragment having TGF- $\alpha$  activity. Contacting the cells with a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, mimetic, or a fragment having TGF- $\alpha$  activity is typically achieved by contacting the cell directly, *e.g.*, soluble form or recombinantly expressed by a cell or immobilized on a solid surface, or by introducing  
10 into the cell a recombinant nucleic acid expressing a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, mimetic, or a fragment having TGF- $\alpha$  activity.

The invention also provides a class of peptides, including TGF- $\alpha$  and those smaller than the 50 amino acid human TGF- $\alpha$ , yet retaining TGF- $\alpha$  biological  
15 activity, which are useful as pharmacologic and therapeutic agents. Other polypeptides or fragments thereof include TGF-related polypeptides that have the biological activity of TGF- $\alpha$  (*e.g.*, amphiregulin, vaccinia growth factor, myxomavirus growth factor (MGF), Shope fibroma virus growth factor (SFGF), heparin-binding EGF-like growth factor (HB-EGF)).

20 The least differentiated cell in a cell lineage is termed a stem cell. However, "stem cell" is an operational term. The classic definition of the stem cell is a cell which can divide to produce another stem cell (self-renewal capacity), as well as a cell which can differentiate along multiple specific differentiation paths. A stem cell  
25 is not a lineage restricted cell but is a cell that can be induced to differentiate down a lineage restricted path. It is often the case that a particular cell within a differentiation lineage, has derived from a "less" differentiated parent and can still divide and give rise to a "more" differentiated cellular progeny.

30 A "precursor cell" or "progenitor cell" has specific biochemical properties, may or may not divide and can be triggered to adopt a different differentiation state

but not necessarily a fully differentiated state, by responding to specific developmental signals. The terms “precursor cell” and “stem cell” are often used interchangeably herein. The stem cells can be any stem cells or tissue precursor cells as described below.

5

Stem cell or precursor cells that can be stimulated *in vivo* to proliferate, migrate and/or differentiate when contacted by a TGF- $\alpha$  polypeptide, a related polypeptide, mimetic, or functional fragment thereof having TGF- $\alpha$  activity, include adult stem cells and precursor cells. Such stem cells and precursor cells include, for  
10 example, cells of neuronal tissue, urogenital tissue (*e.g.*, kidney tissue), gastrointestinal tissue, musculoskeletal tissue, cardiovascular tissue, epithelial (*e.g.*, keratinocyte precursor cells, intestinal precursor cells), and endothelial cells. Stem and precursor cells are discussed more fully below with respect to their location, properties, as well as methods of isolation.

15

TGF- $\alpha$  has recently been identified as useful for treating subjects with neurological deficits. The mechanism of action is thought to include stimulation, proliferation and migration of stem cells of neural origin to sites or lesions in a deficit. For example, Parkinson's Disease is characterized by resting tremor, rigidity, inability  
20 to initiate movement (akinesia) and slowness of movement (bradykinesia). The motor deficits are associated with progressive degeneration of the dopaminergic innervation to the nucleus accumbens and degeneration of noradrenergic cells of the locus ceruleus and serotonergic neurons of the raphe. Up to 80% of nigral dopamine neurons can be lost before significant motor deficits are manifest. TGF- $\alpha$ , when  
25 infused into rat brains over a period of time (*e.g.*, days or weeks), is useful for the treatment of neurodegenerative disorders. Intracerebroventricular (ICV) or intrastriatal infusions of TGF- $\alpha$  over a period of 18 days induced neuronal stem cell proliferation, but degenerating, damaged or otherwise abnormal cells are present to facilitate migration of the neuronal stem cells to a site of injury on a scale sufficient to  
30 impact recovery from an associated neurological deficit (see PCT publication WO 99/06060, incorporated herein by reference in its entirety). Forebrain neural stem

cells migrate and affect treatment and recovery from a neurological deficit disorder including, for example, Parkinson's Disease, Huntington's Disease, Alzheimer's Disease and the like.

5           As used herein, a polynucleotide or a nucleic acid sequence refers to a polymeric form of nucleotides. In some instances a polynucleotide refers to a sequence that is not immediately contiguous with either of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. The term therefore includes,  
10   for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (*e.g.*, a cDNA) independent of other sequences. The nucleotides of the invention can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. In addition, the  
15   polynucleotide sequence involved in producing a polypeptide chain can include regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons) depending upon the source of the polynucleotide sequence.

          The term polynucleotide(s) generally refers to any polyribonucleotide or  
20   polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as used herein refers to, among others, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be  
25   single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.

          In addition, the polynucleotides or nucleic acid sequences may contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs

or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein.

Nucleic acid sequences can be created which encode a fusion protein (*e.g.*, a TGF- $\alpha$  polypeptide and another polypeptide, such as a targeting sequence) and can be  
5 operatively linked to expression control sequences. "Operatively linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For example, a coding sequence is "operably linked" to another coding sequence when RNA polymerase will transcribe the two coding sequences into a single mRNA, which is then translated into a single polypeptide  
10 having amino acids derived from both coding sequences. The coding sequences need not be contiguous to one another so long as the expressed sequences ultimately process to produce the desired protein. An expression control sequence operatively linked to a coding sequence is ligated such that expression of the coding sequence is achieved under conditions compatible with the expression control sequences. As used herein, the term  
15 "expression control sequences" refers to nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operatively linked. Expression control sequences are operatively linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence. Thus, expression control sequences can include  
20 appropriate promoters, enhancers, transcription terminators, a start codon (*i.e.*, ATG) in front of a protein-encoding gene, splicing signals for introns, maintenance of the correct reading frame of that gene to permit proper translation of the mRNA, and stop codons. The term "control sequences" is intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose  
25 presence is advantageous, for example, leader sequences and fusion partner sequences. Expression control sequences can include a promoter.

By "promoter" is meant minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell-type specific, tissue-specific,  
30 or inducible by external signals or agents; such elements may be located in the 5' or 3'

regions of the of a polynucleotide sequence. Both constitutive and inducible promoters, are included in the invention (see *e.g.*, Bitter *et al.*, Methods in Enzymology 153:516-544, 1987). For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage, plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used. When cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (*e.g.*, metallothionein promoter) or from mammalian viruses (*e.g.*, the retrovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5K promoter) may be used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the nucleic acid sequences of the invention. Tissue-specific regulatory elements may be used. Including, for example, regulatory elements from genes or viruses that are differentially expressed in different tissues. For example, a variety of promoters have been identified which are suitable for up regulating expression in cardiac tissue. Included, for example, are the cardiac I-myosin heavy chain (AMHC) promoter and the cardiac I-actin promoter. Other examples of tissue-specific regulatory elements include, tissue-specific promoters, such as milk-specific (whey), pancreatic (insulin or elastase), actin promoter in smooth muscle cells or neuronal (myelin basic protein) promoters such as GFAP (specific for glial cells; see also U.S. Patent No. 6,066,7260). Tissue specific promoters include the 5' or 3' flanking sequences of the beta-globin, elastase, alpha-fetoprotein, alpha-A crystalline, an erythroid specific transcriptional element and insulin genes (Yee, *et al.*, Proc. Natl. Acad. Sci., U.S.A. 86:5873-5877, 1989; Swift, *et al.*, Cell 38:639, 1984; Storb *et al.*, Nature (Lond.) 310:238; Grosschedl *et al.*, Cell 41:885, 1985; Shani, Nature (Lond) 314:238, 1985; and Chada *et al.*, Nature (Lond), 1985). In a another embodiment suitable promoters and/or enhancers may be selected from mammary gland specific genes which are normally only expressed in milk, for example the genes encoding  $\alpha$ -casein (Gene Pharming, Leiden, Netherlands),  $\beta$ -casein (Genzyme Transgenics Corp. Framingham, Mass.),  $\gamma$ -casein,  $\kappa$ -casein,  $\alpha$ -lactalbumin,  $\beta$ -lactalbumin,  $\beta$ -lactoglobulin (PPL Therapeutics Ltd, Edinburgh, Scotland) and whey acidic protein (Altra Bio Inc., Arden Hills Minn.). Methods for targeting recombinant gene expression to the mammary gland of a mammal are described, for example, in U.S. Pat. No. 5,304,489.

A nucleic acid sequence of the invention including, for example, a polynucleotide encoding a fusion protein, may be inserted into a recombinant expression vector. A recombinant expression vector generally refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of a nucleic acid sequences. For example, a recombinant expression vector of the invention includes a polynucleotide sequence encoding a TGF- $\alpha$  polypeptide, related polypeptides, fragments or mimetics thereof having a sequence as set forth in SEQ ID NO:1, 2, 3, 4 or 6 or fragment thereof (as described more fully below). The expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells. Vectors suitable for use in the invention include, but are not limited to the T7-based expression vector for expression in bacteria (Rosenberg, *et al.*, Gene 56:125, 1987), the pMSXND expression vector for expression in mammalian cells (Lee and Nathans, J. Biol. Chem. 263:3521, 1988), baculovirus-derived vectors for expression in insect cells, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV. The nucleic acid sequences of the invention can also include a localization sequence to direct the indicator to particular cellular sites by fusion to appropriate organellar targeting signals or localized host proteins. For example, a polynucleotide encoding a localization sequence, or signal sequence, can be used as a repressor and thus can be ligated or fused at the 5' terminus of a polynucleotide encoding a polypeptide or a polypeptide fragment of the invention such that the localization or signal peptide is located at the amino terminal end of a resulting polypeptide. The construction of expression vectors and the expression of genes in transfected cells involves the use of molecular cloning techniques also well known in the art. (See, for example, Sambrook *et al.*, Molecular Cloning --A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989, and Current Protocols in Molecular Biology, M. Ausubel *et al.*, eds., (Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., most recent Supplement)). These methods include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination/genetic recombination. (See also, Maniatis, *et al.*, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., 1989).

The vectors of the invention can be used to transform a host cell. By transform or transformation is meant a permanent or transient genetic change induced in a cell following incorporation of new DNA (*i.e.*, DNA exogenous to the cell). Where the cell is a mammalian cell, a permanent genetic change is generally achieved by introduction  
5 of the DNA into the genome of the cell.

A transformed cell or host cell generally refers to a cell (*e.g.*, prokaryotic or eukaryotic) into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a polynucleotide molecule encoding a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, mimetic, or a fragment having TGF- $\alpha$  activity  
10 (*e.g.*, a functional fragment as set forth in SEQ ID NO:4, as described below).

Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as *E. coli*, competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated  
15 by the  $\text{CaCl}_2$  method by procedures well known in the art. Alternatively,  $\text{MgCl}_2$  or  $\text{RbCl}$  can be used. Transformation can also be performed after forming a protoplast of the host cell or by electroporation.

When the host is a eukaryote, methods of transfection or transformation with DNA include calcium phosphate co-precipitates, conventional mechanical procedures  
20 such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors, as well as others known in the art, may be used. Eukaryotic cells can also be co-transfected with DNA sequences encoding a TGF- $\alpha$  polypeptide, mimetic or fragment and a second foreign DNA molecule encoding a selectable marker, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral  
25 vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein. (Eukaryotic Viral Vectors, Cold Spring Harbor Laboratory, Gluzman ed., 1982). Typically, a eukaryotic host will be utilized as the host cell. The eukaryotic cell may be a yeast cell (*e.g.*, *Saccharomyces*



cerevisiae), an insect cell (*e.g.*, *Drosophila sp.*) or may be a mammalian cell, including a human cell.

Eukaryotic systems, and mammalian expression systems, allow for post-translational modifications of expressed mammalian proteins to occur. Eukaryotic cells which possess the cellular machinery for processing of the primary transcript, glycosylation, phosphorylation, and, advantageously secretion of the gene product should be used. Such host cell lines may include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, Jurkat, HEK-293, and WI38.

Mammalian cell systems which utilize recombinant viruses or viral elements to direct expression may be engineered. For example, when using adenovirus expression vectors, a polynucleotide encoding a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, mimetic, or a fragment having TGF- $\alpha$  activity may be ligated to an adenovirus transcription/ translation control complex, *e.g.*, the late promoter and tripartite leader sequence. This chimeric sequence may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (*e.g.*, region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a TGF- $\alpha$  polypeptide or fragment thereof in infected hosts (*e.g.*, see Logan & Shenk, Proc. Natl. Acad. Sci. USA, 81:3655-3659, 1984). Alternatively, the vaccinia virus 7.5K promoter may be used. (*e.g.*, see, Mackett, *et al.*, Proc. Natl. Acad. Sci. USA, 79:7415-7419, 1982; Mackett, *et al.*, J. Virol. 49:857-864, 1984; Panicali, *et al.*, Proc. Natl. Acad. Sci. USA 79:4927-4931, 1982). Of particular interest are vectors based on bovine papilloma virus which have the ability to replicate as extrachromosomal elements (Sarver, *et al.*, Mol. Cell. Biol. 1:486, 1981). Shortly after entry of this DNA into mouse cells, the plasmid replicates to about 100 to 200 copies per cell. Transcription of the inserted cDNA does not require integration of the plasmid into the host's chromosome, thereby yielding a high level of expression. These vectors can be used for stable expression by including a selectable marker in the plasmid, such as the *neo* gene. High level expression may also be achieved using inducible promoters, including, but not limited to, the metallothionine IIA promoter and heat shock promoters.

For long-term, high-yield production of recombinant TGF polypeptides, mimetics and functional fragments, stable expression is preferred. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with the cDNA encoding a TGF- $\alpha$  polypeptide, mimetic or functional fragment controlled by appropriate expression control elements (*e.g.*, promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. The selectable marker in the recombinant vector confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. For example, following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. A number of selection systems may be used, including, but not limited to, the herpes simplex virus thymidine kinase (Wigler, *et al.*, Cell, 11:223, 1977), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 48:2026, 1962), and adenine phosphoribosyltransferase (Lowy, *et al.*, Cell, 22:817, 1980) genes can be employed in tk-, hgp<sup>r</sup>t- or ap<sup>r</sup>t- cells respectively. Also, anti-metabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler, *et al.*, Proc. Natl. Acad. Sci. USA, 77:3567, 1980; O'Hare, *et al.*, Proc. Natl. Acad. Sci. USA, 8:1527, 1981); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 78:2072, 1981); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, *et al.*, J. Mol. Biol. 150:1, 1981); and hyg<sup>r</sup>, which confers resistance to hygromycin (Santerre, *et al.*, Gene 30:147, 1984) genes. Recently, additional selectable genes have been described, namely trpB, which allows cells to utilize indole in place of tryptophan; hisD, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, Proc. Natl. Acad. Sci. USA 85:8047, 1988); and ODC (ornithine decarboxylase) which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue L., In: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, ed., 1987).

The term "primer" as used herein refers to an oligonucleotide, whether natural or synthetic, which is capable of acting as a point of initiation of synthesis when placed

under conditions in which primer extension is initiated or possible. Synthesis of a primer extension product which is complementary to a nucleic acid strand is initiated in the presence of nucleoside triphosphates and a polymerase in an appropriate buffer at a suitable temperature.

5           A polypeptide or protein refers to a polymer in which the monomers are amino acid residues which are joined together through amide bonds. When the amino acids are alpha-amino acids, either the L-optical isomer or the D-optical isomer can be used, the L-isomers being typical. A TGF- $\alpha$  polypeptide, a related polypeptide, mimetic, or functional fragment thereof is intended to encompass an amino acid sequence, including  
10   modified sequences such as glycoproteins, which exhibit TGF- $\alpha$  activity. The molecules (*e.g.*, polypeptides) of the invention encompass amino acid sequences of human TGF- $\alpha$  as shown in SEQ ID NO:1 as well as polypeptides that have structural and/or functional characteristics of TGF- $\alpha$ . For example, a polypeptide or a TGF- $\alpha$  related polypeptide of the invention may include a polypeptide that shares a cysteine disulfide  
15   bond structure similar to TGF- $\alpha$  such as a related family of proteins including vaccinia growth factor, amphiregulin precursor, betacellulin precursor, heparin binding EGF-like growth factor, epiregulin (rodent only), HUS 19878, myxomavirus growth factor (MGF), Shope fibroma virus growth factor (SFGE), and schwannoma derived growth factor. In addition, a molecules (*e.g.*, a polypeptide) of the invention  
20   will have one or more functional characteristics related to TGF- $\alpha$  including, for example, the ability to interact with an EGF family receptor member, stimulate proliferation or migration of stem cells, or to treat or prevent cachexia.

          The polypeptides of the invention are intended to cover substantially purified  
25   naturally occurring proteins, as well as those which are recombinantly or synthetically synthesized. In addition, a TGF- $\alpha$  or related polypeptide can occur in at least two different conformations wherein both conformations have the same or substantially the same amino acid sequence but have different three dimensional structures so long as the have a biological activity related to TGF- $\alpha$ . Polypeptide or protein fragments of TGF- $\alpha$   
30   are also encompassed by the invention such as those described below (*e.g.*, by formulas I, II, and III). Fragments can have the same or substantially the same amino acid

sequence as the naturally occurring protein. A polypeptide or peptide having substantially the same sequence means that an amino acid sequence is largely, but not entirely, the same, but retains a functional activity of the sequence to which it is related. In general polypeptides of the present invention include peptides, or full length protein, that contain substitutions, deletions, or insertions into the protein backbone, that would still have an approximately 50%-70% homology to the original protein over the corresponding portion. A yet greater degree of departure from homology is allowed if like-amino acids, *i.e.* conservative amino acid substitutions, do not count as a change in the sequence. A TGF- $\alpha$  polypeptide fragments of the invention retains a biological activity associated with TGF- $\alpha$  as described above.

Homology to TGF- $\alpha$  polypeptide can be measured using standard sequence analysis software (*e.g.*, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705; also see Ausubel, *et al.*, *supra*). Such procedures and algorithms include, for example, a BLAST program (Basic Local Alignment Search Tool at the National Center for Biological Information), ALIGN, AMAS (Analysis of Multiply Aligned Sequences), AMPS (Protein Multiple Sequence Alignment), ASSET (Aligned Segment Statistical Evaluation Tool), BANDS, BESTSCOR, BIOSCAN (Biological Sequence Comparative Analysis Node), BLIMPS (BLOCKS IMPROVED Searcher), FASTA, Intervals & Points, BMB, CLUSTAL V, CLUSTAL W, CONSENSUS, LCONSENSUS, WCONSENSUS, Smith-Waterman algorithm, DARWIN, Las Vegas algorithm, FNAT (Forced Nucleotide Alignment Tool), Framealign, Framesearch, DYNAMIC, FILTER, FSAP (Fristensky Sequence Analysis Package), GAP (Global Alignment Program), GENAL, GIBBS, GenQuest, ISSC (Sensitive Sequence Comparison), LALIGN (Local Sequence Alignment), LCP (Local Content Program), MACAW (Multiple Alignment Construction & Analysis Workbench), MAP (Multiple Alignment Program), MBLKP, MBLKN, PIMA (Pattern-Induced Multi-sequence Alignment), SAGA (Sequence Alignment by Genetic Algorithm) and WHAT-IF.

30

A polypeptide may be substantially related but for a conservative variation, such polypeptides being encompassed by the invention. A conservative variation denotes the replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue such as  
5 isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, and the like. Other illustrative examples of conservative substitutions include the changes of: alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine  
10 to asparagine; glutamate to aspartate; glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine, glutamine, or glutamate; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; valine to isoleucine to leucine. The  
15 term "conservative variation" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.

Modifications and substitutions are not limited to replacement of amino acids.  
20 For a variety of purposes, such as increased stability, solubility, or configuration concerns, one skilled in the art will recognize the need to introduce, (by deletion, replacement, or addition) other modifications. Examples of such other modifications include incorporation of rare amino acids, dextra (D)-amino acids, glycosylation sites, cytosine for specific disulfide bridge formation. The modified peptides can be  
25 chemically synthesized, or the isolated gene can be site-directed mutagenized, or a synthetic gene can be synthesized and expressed in bacteria, yeast, baculovirus, tissue culture and so on.

Solid-phase chemical peptide synthesis methods can also be used to synthesize the polypeptide or fragments of the invention. Such method have been known in the art  
30 since the early 1960's (Merrifield, R. B., J. Am. Chem. Soc., 85, 2149-2154 (1963) (See also Stewart, J. M. and Young, J. D., Solid Phase Peptide Synthesis, 2 ed., Pierce

Chemical Co., Rockford, Ill., pp. 11-12)) and have recently been employed in commercially available laboratory peptide design and synthesis kits (Cambridge Research Biochemicals). Such commercially available laboratory kits have generally utilized the teachings of H. M. Geysen *et al*, Proc. Natl. Acad. Sci., USA, 81, 3998  
5 (1984) and provide for synthesizing peptides upon the tips of a multitude of “rods” or “pins” all of which are connected to a single plate. When such a system is utilized, a plate of rods or pins is inverted and inserted into a second plate of corresponding wells or reservoirs, which contain solutions for attaching or anchoring an appropriate amino acid to the pin’s or rod’s tips. By repeating such a process step, *i.e.*, inverting and inserting  
10 the rod and pin tips into appropriate solutions, amino acids are built into desired peptides. In addition, a number of available Fmoc peptide synthesis systems are available. For example, assembly of a polypeptide or fragment can be carried out on a solid support using an Applied Biosystems, Inc. Model 431A automated peptide synthesizer. For example, if the peptide is from formula I or formula II (see below), a  
15 preferred means for synthesizing peptides of 10-18 amino acids in length is by direct peptide synthesis generally starting with the N-terminal amino acid and adding amino acids in the C terminal direction. TGF $\alpha$  has been made using recombinant techniques and is available as a laboratory reagent commercially. The bifunctional compounds of formula III are best synthesized with each loop peptide moiety synthesized and  
20 then added to the heterocyclic nitrogen atom using standard heterocyclic addition synthesis.

The invention provides a TGF- $\alpha$  polypeptide, a related polypeptide, mimetic, or functional fragment thereof having TGF- $\alpha$  activity. The functional fragments and mimetics have an altered (compared to the naturally occurring molecule) sequence,  
25 for example, the N-terminal region of TGF- $\alpha$  (defined as the first seven N-terminal amino acids before the first loop region) and an altered “tail” region (defined as the last seven amino acids at the C-terminus after the third loop region) can be modified, truncated or deleted as described more fully herein. The alterations to the fifty amino acid sequence of human TGF- $\alpha$  (SEQ ID NO:1) caused by deletion of some or all of  
30 the seven amino acids at the N-terminal region resulted in a polypeptides having

about 90% of the biological activity of the TGF- $\alpha$  having a sequence as set forth in SEQ ID NO:1. In addition, substitution of D amino acids for natural L amino acids in the N-terminal region results in retention of TGF- $\alpha$  biological activity and an increase in plasma half life of the polypeptide after intravenous administration. Truncation of the N-terminus by 6 residues leaves a Lys residue at amino acid position 7 which provides for two free amino groups. This provides a site for forming a PEG (polyethylene glycol) "PEGalated TGF $\alpha$  mimetic" to be synthesized and further provides for improved pharmacokinetic benefits, including resistance to proteolytic enzyme breakdown.

10

In one embodiment, the TGF- $\alpha$  polypeptide, related polypeptide, mimetic or functional fragment is a TGF- $\alpha$  polypeptide as set forth in SEQ ID NO:1, SEQ ID NO:3, or a TGF $\alpha$  mimetic selected from the group consisting of formula I, formula II, formula III, formula IV, or formula V, wherein formula I is:

15  $R_1 - T - R_2$  (I)

wherein  $R_1$  is  $-NH_2$ ,  $R_1$  is  $R_3 - X_3$  wherein  $R_3$  is a polyethylene glycol (PEG) attached to the free  $NH_2$  moiety of  $X_3$  (wherein  $X_3$  is Lys or Arg) and having a molecular weight of PEG of from about 2000 daltons to about 10,000 daltons, or one or more of the following seven amino acids from formula VI, including either L (natural) or D chiral amino acids:


20  $-NH_2 - X_{1a} - X_{1a} - Ser - His - Phe - Gln - X_3 -$  (IV)

wherein  $X_1$  is independently Val, Gly or Ala and  $X_3$  is Lys or Arg; wherein T is the native sequence of human TGF $\alpha$  (SEQ ID NO:1) from amino acid residue no. 8 (Cys) to amino acid residue no. 44 (Cys) consisting of native L amino acids; and wherein  $R_2$  is  $-COOH$  or one or more of the following seven amino acids, including either L (natural) or D chiral orientations, from formula V:


25  $- X_4 - His - X_{1c} - X_4 - X_5 - X_6 - X_{1c}$  (V)

wherein  $X_4$  is Glu or Asp, wherein  $X_5$  is Leu or Ile, wherein  $X_6$  is Asp or Glu, and wherein  $X_1$  is independently Val, Gly or Ala.


30 The invention provides a peptide having TGF $\alpha$  biological activity, comprising at least an 11-membered peptide compound of formula II (SEQ ID NO:4):



wherein  $X_1$  is independently Val, Gly or Ala, wherein  $X_2$  is Tyr or Phe, wherein  $X_3$  is Arg or Lys, and wherein the two Cys moieties form a disulfide bond to create an 11-amino acid functional peptide having a 10 member loop structure. In addition, at least one or more of the following amino acids of formula III (SEQ ID NO:5) may be added to the C terminus Cys moiety of formula I (SEQ ID NO:4):



wherein  $X_4$  is Glu or Asp, wherein  $X_5$  is Leu or Ile, and wherein  $X_6$  is Asp or Glu. Preferably,  $X_{1a}$  is Val,  $X_{1b}$  is Gly and  $X_{1c}$  is Ala thereby producing an 11, 12, 13, 14, 15, 16, 17 or 18 amino acid peptide. Preferably,  $X_2$  is Tyr, and  $X_3$  is Arg. Accordingly, in one embodiment the functional peptide of the invention has a sequence:



SEQ ID NO:6 forms a 10 member loop structure with a 7 member tail that can be varied in length. In addition, SEQ ID NO:6 can form dimers comprising, for example, a 34-mer peptide. Accordingly, the functional peptide can be from about 10 to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein  $X_{1a}$  is Val,  $X_{1b}$  is Gly,  $X_{1c}$  is Ala and  $X_4$  is Gly and may also comprise hetero- or homo-dimers of various TGF- $\alpha$  peptides described herein. Such dimers may have greater or reduced activities as compared to monomers.

The invention further provides an active TGF- $\alpha$ 57 polypeptide (SEQ ID NO:3), wherein TGF- $\alpha$ 57 is a 57 amino acid polypeptide having the formula VI:



Ser - Leu - Ser - Leu - Pro - Ala - Met - Human TGF $\alpha$  (VI)

wherein human TGF $\alpha$  is a 50 amino acid polypeptide having a sequence as set forth in SEQ ID NO:1.

5

By "functional" as used in connection with the peptides or peptide fragments of the invention is meant that the peptides or fragments have TGF- $\alpha$  activity. This biological activity is associated with the peptides of formula I, formula II and formula III and the data available for TGF $\alpha$ .

10

The functional peptides of the invention are based, in part, upon the discovery that a loop peptide of TGF- $\alpha$  exhibits TGF- $\alpha$  biological activity and can therefore stimulate multipotent precursor cells to divide and migrate. This activity indicates that the loop peptide is effective to treat a number of diseases and disorder associated with tissue damage or injury including, for example, neurological deficits caused by a wide variety of diseases and injuries that each result in a neurological deficit in some specific area of the brain or specific kind of neuron. These include degenerative diseases, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), and Huntington's Disease (HD), Pick's disease, progressive supranuclear palsy, striatonigral degeneration, cortico-basal degeneration, olivopontocerebellar atrophy, Leigh's disease, infantile necrotizing encephalomyelopathy, Hunter's disease, mucopolysaccharidosis, various leukodystrophies (such as Krabbe's disease, Pelizaeus-Merzbacher disease and the like), amaurotic (familial) idiocy, Kuf's disease, Spielmeier-Vogt disease, Tay Sachs disease, Batten disease, Jansky-Bielschowsky disease, Reye's disease, cerebral ataxia, chronic alcoholism, beriberi, Hallervorden-Spatz syndrome, cerebellar degeneration, and the like.

Accordingly, in one embodiment, a TGF-  $\alpha$  polypeptide, fragment or mimetic can be used to treat, repair or regenerate a tissue or a subject having an injury. In one embodiment, the invention provides a continuous infusion of a TGF- $\alpha$  polypeptide, a related polypeptide, mimetic, or functional fragment thereof having TGF- $\alpha$  activity at

the site of injury or at a site that allows for delivery of the TGF-  $\alpha$  polypeptide, fragment or mimetic to the site of injury (*e.g.*, a vein or portal upstream of the injured site). The TGF- $\alpha$  polypeptide, a related polypeptide, mimetic, or functional fragment thereof having TGF- $\alpha$  activity of the invention delivered to the site of injury promotes  
5 stem cell proliferation, migration, and/or differentiation of stem cells or precursor cells at the site of injury and thus promotes tissue repair and regeneration. Any number of tissues can be treated, repaired or regenerated, including kidney tissue, liver tissue, spleen tissue, bone tissue, neural tissue, skin tissue, gastrointestinal tissue, urogenital tissue, and musculoskeletal tissue. It is contemplated that certain tissues  
10 may be excluded from the invention (*e.g.*, brain tissue). For example, administration or delivery of a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, mimetic, or a fragment having TGF- $\alpha$  activity at the site of injury within the gastrointestinal tract results in a renewal and regeneration of the villi and epithelial cells lining the gastrointestinal tract. In addition, similar results were seen in kidney and spleen tissues.

15

Further, injuries (traumatic or neurotoxic) that cause a loss of neuronal function can be treated by the functional polypeptides and mimetics of the invention. Reid *et al.* describes the continuous infusion of TGF- $\alpha$  into brain tissue following injury (see, WO 99/06060, and U.S. Patent Application 09/129,028 which are  
20 incorporated herein by reference in their entirety). The present invention describes methods whereby continuous infusion into various injured tissues or bolus delivery of a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, mimetic, or a fragment having TGF- $\alpha$  activity either before, prior to, simultaneous with or following tissue injury can stimulate stem cells in the damaged or injured tissue to proliferate, migrate from  
25 tissue adjacent to the damaged tissue, and differentiate to replace or repair cells at the site of injury.

Injuries treatable by the methods of the invention include, for example, gunshot wounds, injuries caused by blunt force, penetration injuries, injuries caused  
30 by surgical procedure (*e.g.*, tumor removal, abscess removal, epilepsy lesion removal) poisoning (*e.g.*, carbon monoxide), shaken baby syndrome, adverse reactions to

medications, drug overdoses, and post-traumatic encephalopathy. Ischemia can further cause CNS injury due to disruption of blood flow or oxygen delivery that can kill or injure neurons and glial cells (*e.g.*, TGF- $\alpha$  confers protection from ischemia in a porcine gastrointestinal model and a family member, Heparin-binding EGF, confers protection from ischemia in a rat stroke model). Such injuries can be treated by administration of the functional peptides and include, for example, injuries caused by stroke, anoxia, hypoxia, partial drowning, myoclonus, severe smoke inhalation, dystonias, and acquired hydrocephalus. Developmental disorders that can be treated by the functional peptides include, for example, schizophrenia, certain forms of severe mental retardation, cerebral palsy, congenital hydrocephalus, severe autism, Downs Syndrome, LHRH/hypothalamic disorder, and spina bifida. The functional peptides can be further used to treat disorders affecting vision caused by the loss or failure of retinal cells and include, for example, diabetic retinopathy, serious retinal detachment (associated with glaucoma), traumatic injury to the retina, retinal vascular occlusion, macular degeneration, optic nerve atrophy and other retinal degenerative diseases. Injuries to the spinal cord can be treated by the functional peptides. Examples of spinal cord injuries are post-polio syndrome, amyotrophic lateral sclerosis, traumatic injury, surgical injury, and paralytic diseases. Demyelinating autoimmune disorders can be treated by administration of the functional peptides and include, for example, multiple sclerosis. The functional peptides can also be used to treat neurological deficits caused by infection of inflammatory diseases, including, for example, Creutzfeldt-Jacob disease and other slow virus infectious diseases of the CNS, AIDS encephalopathy, post-encephalitic Parkinsonism, viral encephalitis, bacterial meningitis and other CNS effects of infectious diseases.

25

Generally, the terms “treating”, “treatment” and the like are used herein to mean affecting a subject, tissue or cell to obtain a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or disorder or sign or symptom thereof, and/or may be therapeutic in terms of a partial or complete cure for a disorder or disease and/or adverse effect attributable to the disorder or disease. “Treating” as used herein covers any treatment of, or prevention of,

30

or inhibition of a disorder or disease in a subject. The subject can be an invertebrate, a vertebrate, a mammal, and particularly a human, and includes by way of example: (a) preventing the disease or disorder from occurring in a subject that may be predisposed to the disease or disorder, but has not yet been diagnosed as having it; (b) inhibiting the  
5 disease or disorder, *i.e.*, arresting its progression; or (c) relieving or ameliorating the disease or disorder, *i.e.*, causing regression. Thus, treating as used herein includes, for example, repair and regeneration of damaged or injured tissue or cells at the site of injury or prophylactic treatments to prevent damage, *e.g.*, before chemotherapy.

In another embodiment, a single bolus of a TGF- $\alpha$  polypeptide, a related  
10 polypeptide, mimetic, or functional fragment thereof, having TGF- $\alpha$  activity, is administered prior to, contemporaneously with, or subsequent to a tissue injury. Typically a single dose injection will be a few hours, a few days or a few weeks after tissue injury. The present invention is based in part upon the discovery that a TGF- $\alpha$  polypeptide, a related polypeptide, mimetic, or functional fragment thereof having TGF-  
15  $\alpha$  activity induces stem cell proliferation, migration, and/or differentiation at the site of tissue injury. A single unit dosage delivery can be immediately adjacent to the site of injury or can be, for example, to a vessel that drains or flows to the site of injury.

A TGF- $\alpha$ , TGF $\alpha$ 57 polypeptide, related polypeptides, fragments thereof or a  
20 TGF- $\alpha$  mimetic is administered initially at a point in time prior to the time of damage of the target organ or tissue. In one embodiment, a TGF- $\alpha$  polypeptide, fragments, or mimetic is administered initially prior to administration of a cytotoxic agent.

In yet another embodiment, a single bolus of a TGF- $\alpha$  polypeptide, a related  
25 polypeptide, mimetic, or functional fragment thereof, having TGF- $\alpha$  activity, can be followed by subsequence administrations of a TGF- $\alpha$  polypeptide, a related polypeptide, mimetic, or functional fragment as continuous infusions or additional single bolus deliveries. In addition, it is contemplated that additional therapeutic agents can be combined with, administered prior to or subsequent to administration of a TGF- $\alpha$   
30 polypeptide, a related polypeptide, mimetic, or functional fragment thereof.

In still another embodiment, a TGF- $\alpha$  polypeptide, a related polypeptide, mimetic, or functional fragment thereof having TGF- $\alpha$  activity are useful as vaccine adjuvants to increase mucosal humoral immunity. When a TGF- $\alpha$ 57 polypeptide was administered to mice (10-50  $\mu$ g/kg ip for 3 successive days or 10-50  $\mu$ g/kg iv for 2 successive days or 10  $\mu$ g/kg sc every day for 3-5 successive days) histological examination of lymphoid tissues such as spleen and the large intestine showed an increase in T cell progenitor cells. Histological staining showed increased T cell progenitors as compared with untreated mice and appeared as new germinal foci. Such T cell progenitors positioned in the gastrointestinal tract represent a reservoir for CD4 helper cells needed against mucosal directed vaccine production mediated by priming with exogenous antigen. The T cell progenitor cells appear to be double null and thus naive. Accordingly, the T cell progenitor cell response to TGF- $\alpha$  and TGF- $\alpha$  mimetics provides the utility for such compounds to provide a strong mucosal immunity response and usefulness as a mucosal vaccine and as a universal stem cell adjuvant.

During a course of therapy organs may be targeted by specific chemical agents, however, organ damage can be a side effect. In United States patent application 09/299,473 filed 26 April 1999 (the disclosure of which is incorporated by reference herein), the effects of increasing hematopoiesis based upon hematopoietic injury from cytotoxic cancer therapy is described. These data can be further expanded to organ damage caused by chemicals known to cause specific organ damage. As shown below, gentamycin is an antibiotic known to cause kidney damage as a dose-limiting side effect. Histological data shows that the kidney damage seen in glomeruli of kidneys is alleviated by concurrent and subsequent administration of a TGF- $\alpha$  polypeptide (in this case a TGF- $\alpha$ 57 polypeptide was used). Kidney damage can also occur following exposure to cancer chemotherapeutic agent, such as cis platinum, or gentamycin or the toxin from *E. coli* 0H1:37 from undercooked contaminated meats. Intestinal damage can occur from many cancer chemotherapeutic agents, cholera toxin, and the like. Lungs can be damaged by the anti-cancer agent bleomycin.

Accordingly, administration of a TGF- $\alpha$  polypeptide, fragments, or mimetic before, during and following exposure to an organ toxic agent can prevent organ damage.

In addition, administration of a TGF- $\alpha$  polypeptide, fragments, and mimetic to regenerate damaged tissue, for example, in kidney, an organ sensitive to such damage, is also disclosed herein. In an *in vivo* experiment, mice were administered 10 mg/kg of Cis-platinum as a single ip injection and treated mice administered 10  $\mu$ g/kg a human TGF- $\alpha$ 57 (R&D Systems, Minneapolis, MN). TGF- $\alpha$ 57 was administered just before CP and in two additional doses after, by ip administration for a general systemic effect. Several organs or tissues were collected from the animals sacrificed 4 days after CP dose (or saline for no TGF $\alpha$ 57) and tissues were examined histologically.

H&E stained kidney tissue (primarily glomeruli) that were exposed to the high kidney-damaging CP dose showed extensive damage to the glomerulus with a distortion in the architecture of Bowman's capsule. The cuboidal epithelium of the proximal convoluted tubule was also damaged. Kidneys from control animals exhibited normal morphology. Kidney from a mouse treated with CP and also with (10  $\mu$ g/kg) TGF- $\alpha$ 57 6 hours prior to CP and 24 and 48 hours after CP showed that TGF- $\alpha$ 57 treatment essentially protected the glomeruli from damage.

In another set of *in vivo* experiments, gentamicin (antibiotic having dose-limiting kidney toxicity side effects) was used as the cytotoxic agent for a chronic cytotoxic agent. Eight CD-1 mice were weighed and injected subcutaneously with 80 mg/kg of gentamicin sulfate. Four of the mice were controls and injected with 0.1 ml of 0.9% saline and the other four injected ip with 0.1 ml of 10  $\mu$ g/ml stock of TGF- $\alpha$  (57 aa polypeptide) as a 1  $\mu$ g dose. The mice were reinjected with the same does of saline or TGF- $\alpha$  every 24 hours and every 24 hours subcutaneously with the same does of gentamicin. After two weeks of treatment, the mice were sacrificed and blood BUN and creatinine were measured and the kidneys examined. The average

creatinine values were  $0.49 \pm 0.096$  for controls and  $0.34 \pm 0.042$  for treated mice. The average BUN values were  $36.1 \pm 4.8$  for controls and  $35.5 \pm 4.9$  for treated mice.

In another set of *in vivo* experiments, glycerol (50% (v/v) aqueous solution, Sigma) was used as the cytotoxic agent for an acute cytotoxic agent. Six CD-1 mice were weighed and injected into both hind limbs im with 10 ml/kg of 50% (v/v) glycerol, one half into each hind limb im. Three of the mice were controls and injected with 0.1 ml of 0.9% saline and the other three injected ip with 0.1 ml of 10  $\mu\text{g/ml}$  stock of TGF- $\alpha$  (57 aa polypeptide) as a 1  $\mu\text{g}$  dose. The mice were reinjected with the same does of saline or TGF- $\alpha$  the next day and another equal dose of 50% glycerol. After two treatments, the mice were sacrificed and blood BUN and creatinine was measured and the kidneys examined. The average creatinine values were  $1.75 \pm 0.613$  for controls and  $1.51 \pm 0.940$  for treated mice. The average BUN values were  $1172.8 \pm 38.0$  for controls and  $165.3 \pm 75.6$  for treated mice.

15

The invention includes various pharmaceutical compositions useful for delivery or administration of the polypeptides, peptides and mimetics of the invention. In one embodiment, the pharmaceutical composition are useful in managing or treating tissue damage and cell renewal in a subject. In another embodiment, the invention provides a method of treating or preventing weight-loss associated with a disorder or disease. Such disorders or diseases include weight-loss attributable to, for example, chemotherapy or a viral infection (*e.g.*, HIV). The pharmaceutical compositions according to the invention are prepared by bringing a polypeptide or peptide derivative of TGF- $\alpha$ , a TGF- $\alpha$  mimetic into a form suitable for administration to a subject using carriers, excipients and additives or auxiliaries. Frequently used carriers or auxiliaries include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water, alcohols, glycerol and polyhydric alcohols. Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobial, anti-oxidants, chelating agents and inert gases. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic

20  
25  
30

excipients, including salts, preservatives, buffers and the like, as described, for instance, in Remington's Pharmaceutical Sciences, 15th ed. Easton: Mack Publishing Co., 1405-1412, 1461-1487 (1975) and The National Formulary XIV., 14th ed. Washington: American Pharmaceutical Association (1975), the contents of which are hereby  
5 incorporated by reference. The pH and exact concentration of the various components of the pharmaceutical composition are adjusted according to routine skills in the art. See Goodman and Gilman's The Pharmacological Basis for Therapeutics (7th ed.).

The pharmaceutical compositions are preferably prepared and administered in dose units. Solid dose units are tablets, capsules and suppositories and including, for  
10 example, alginate based pH dependent release gel caps. For treatment of a subject, depending on activity of the compound, manner of administration, nature and severity of the disorder, age and body weight of the subject, different daily doses are necessary. Under certain circumstances, however, higher or lower daily doses may be appropriate. The administration of the daily dose can be carried out both by single administration in  
15 the form of an individual dose unit or by several smaller dose units and also by multiple administration of subdivided doses at specific intervals.

The pharmaceutical compositions according to the invention may be administered locally or systemically in a therapeutically effective dose. Amounts effective for this use will, of course, depend on the severity of the disease and the weight  
20 and general state of the subject. Typically, dosages used *in vitro* may provide useful guidance in the amounts useful for *in situ* administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders. Various considerations are described, *e.g.*, in Langer, Science, 249: 1527, (1990); Gilman *et al.* (eds.) (1990), each of which is herein  
25 incorporated by reference.

In one embodiment, the invention provides a pharmaceutical composition useful for administering a TGF- $\alpha$  polypeptide or functional fragment, or a nucleic acid encoding a TGF- $\alpha$  polypeptide or functional fragment, to a subject in need of such treatment. "Administering" the pharmaceutical composition of the invention may be



accomplished by any means known to the skilled artisan. Preferably a “subject” refers to a mammal, most preferably a human.

The TGF- $\alpha$  polypeptide or functional fragment can be administered parenterally, enterically, by injection, rapid infusion, nasopharyngeal absorption, dermal absorption, rectally and orally. Pharmaceutically acceptable carrier preparations for parenteral administration include sterile or aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers for occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, aerosols, drops or injectable solution in ampule form and also preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners and elixirs containing inert diluents commonly used in the art, such as purified water. Where the disease or disorder is a gastrointestinal disorder oral formulations or suppository formulations are preferred.

Sterile injectable solutions can be prepared by incorporating the active agent (see formula I, formula II, or formula III and TGF $\alpha$ ) in the required amount (*e.g.*, about 10  $\mu$ g to about 10 mg/kg) in an appropriate solvent and then sterilizing, such as by sterile filtration. Further, powders can be prepared by standard techniques such as freeze drying or vacuum drying.

In another embodiment, the active agent is prepared with a biodegradable carrier for sustained release characteristics for either sustained release in the GI tract or for target organ implantation with long term active agent release characteristics to the intended site of activity. Biodegradable polymers include, for example, ethylene

vinyl acetate, polyanhydrides, polyglycolic acids, polylactic acids, collagen, polyorthoesters, and poly acetic acid. Liposomal formulation can also be used.

In another embodiment, infant formula comprising standard formula  
5 ingredients but supplemented with TGF- $\alpha$ , fragments thereof or mimetics thereof at a concentration of from about 400  $\mu\text{g/kg}$  to about 4 mg/kg in the final formula are provided. TGF- $\alpha$  is a natural occurring small hormone like polypeptide that is found in human mother's milk. It is used by the body to maintain a daily need to regenerate the epithelial cells in the intestinal mucosa during remodeling (which takes place  
10 every 3-5 days). In addition, following GI injury, TGF- $\alpha$  and its receptor (EGF) are upregulated at the site of injury. TGF- $\alpha$  administration can accelerate mucosal repair and to protect mucosal damage caused by acid or aspirin. Moreover, knock-out mice that lack the ability to produce TGF $\alpha$  have their mucosal injury exacerbated. However, higher doses and concentrations are needed for oral delivery as opposed to  
15 parenteral administration.

The present invention further provides a method for expanding stem cells or precursor cells. In one embodiment, the stem cells or precursor cells are expanded *ex vivo*. One method of the invention comprises: culturing stem cells from a subject;  
20 adding TGF- $\alpha$ , a TGF- $\alpha$ 57 polypeptide, a TGF- $\alpha$  mimetic, or a TGF- $\alpha$  functional fragment to the culture medium in an amount effective to augment stem cell growth.

The stem cells can be any stem cells or tissue precursor cells as described below. The precursor cells to be expanded or stimulated *in vitro* or *in vivo*. In one  
25 embodiment of the present invention the cells can be isolated from a variety of sources using methods known to one skilled in the art. The precursor cells can be of ectodermal, mesodermal or endodermal origin. Any precursor cells which can be obtained and maintained *in vitro* can potentially be used in accordance with the invention. In one embodiment, the precursor cell is a stem cell. Such stem cells  
30 include but are not limited to hematopoietic stem cells (HSC), stem cells of epithelial tissues such as the skin and the lining of the gut, embryonic heart muscle cells, and

neural stem cells. The stem cells can be expanded under cell growth conditions, *i.e.*, conditions that promote proliferation (“mitotic activity”) of the cells.

The present invention is also directed to methods for expanding precursor cells  
5 *in vitro* and using the expanded precursor cells for grafting, cell therapy or gene therapy as well as for use in providing desired cell populations and for use in regenerating injured and/or diseased tissues. The expanded precursor cell populations can be administered to a subject using methods commonly known to those skilled in the art.

10

In one embodiment, the precursor cells are expanded *in vitro* and then delivered to a site or tissue in need of repair. Alternatively, the cells may be delivered in conjunction with various delivery vehicles, including biocompatible biodegradable or non-biodegradable sponges (*e.g.*, collagen, or other extracellular matrix materials),  
15 cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, dextran, polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, or a nitrocellulose compound formed into a three-dimensional structure (see, for example, U.S. Patent No. 5,858,721 to Naughton *et al.*, the disclosure of which is incorporated herein by reference).

20

In another embodiment, the precursor cells can be expanded *in vitro* and used in tissue engineering processes. For example, precursor cells can be expanded *in vitro*, applied to a three dimensional scaffold and the precursor cells contacted with various agents or parenchymal cells to induce differentiation down a particular cell  
25 type or tissue type. Alternatively, the cells can be expanded and cultured under physiological conditions that mimic the conditions of the tissue to be derived. Such methods include the culturing of precursor cells expanded with a transforming growth factor alpha or related protein within a bioreactor. Various bioreactor are known in the art and include bioreactors which mimic the environment of cardiovascular tissue  
30 to form tubes or tendons (U.S. Patent 5,863,531), cartilage bioreactors (U.S. Patent 5,928,945), liver bioreactor (U.S. Patent 6,008,049).

In another embodiment, after expansion of the precursor population using a TGF- $\alpha$  polypeptide, fragment or mimetic, the precursor cell can be induced to differentiate *in vivo*, or alternatively *in vitro*, followed by administration to an individual, to provide a differentiated phenotype to a subject.

The invention is also directed to precursor cells expressing recombinant genes, such that the precursor cells express a desired gene. These recombinant precursor cells can be transplanted into a patient such that the desired gene is expressed in a subject to alleviate a disease state caused by the lack of expression of the recombinant gene. The precursor cells can be made recombinant either before or after precursor cell expansion using the TGF- $\alpha$  polypeptides, fragments and mimetics of the invention. Methods of transfecting the nucleic acid encoding the desired gene product such that the precursor cell or its progeny stably expresses the gene product are known to those of skill in the art and are described herein.

The subject into which the expanded cells or their progeny are introduced, or from which precursor cells can be derived, is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably a human.

In one embodiment of the invention, the subjects to which the expanded precursor cells are administered are immunocompromised or immunosuppressed or have an immune deficiency. For example, the subject has Acquired Immune Deficiency Syndrome (AIDS) or has been exposed to radiation or chemotherapy regimens for the treatment of cancer, and the subjects are administered hematopoietic or immune precursor cells such that the administered cells perform a needed immune or hematopoietic function. The expanded precursor cell is may be originally derived from the subject (*i.e.*, autologous) or may be derived from a related subject (*i.e.*, allogeneic) or may be from a different species (*i.e.*, xenogeneic).

Precursor cells can be obtained by any method known in the art. The cells can be obtained directly from tissues of a subject or from cell lines or by production *in vitro* from less differentiated precursor cells, *e.g.*, stem or progenitor cells. An example of obtaining precursor cells from less differentiated cells is described in

5 Gilbert, 1991, Developmental Biology, 3rd Edition, Sinauer Associates, Inc., Sunderland Mass. Briefly, progenitor cells can be incubated in the presence of other tissues or growth and differentiation factors which cause the cell to differentiate. For example, when lung bud epithelium is cultured alone, no differentiation occurs. However, when lung bud epithelium is cultured with stomach mesenchyme or

10 intestinal mesenchyme, the lung bud epithelium differentiates into gastric glands or villi, respectively. Further, if lung bud epithelium is cultured with liver mesenchyme or bronchial mesenchyme, the epithelium differentiates into hepatic cords or branching bronchial buds, respectively.

15 The following describes approaches for the isolation of precursor cells and precursor cell-containing tissues, which are to be contacted with a TGF- $\alpha$  polypeptide, fragment, or mimetic according to the present invention. As already mentioned, isolated cell types or mixed cell populations can be treated with a TGF- $\alpha$  polypeptide, fragment, or mimetic to expand the precursor population. The isolated

20 precursor cell or precursor cell population can be cultured *ex vivo* for proliferation which under the influence of the polypeptides, fragments and mimetics allow for continued growth, *i.e.*, expand, in order to reach the desired numbers. Once expanded the cells can be transplanted or used for production of autologous biological agents. Optionally, a recombinant gene can be introduced into the cell so that it or its progeny

25 expresses a desired gene product before transplantation. Introduction of a recombinant gene can be accomplished either before or after precursor cell expansion.

In a one embodiment, the precursor cell populations are purified or at least highly enriched prior to contacting with a TGF- $\alpha$  polypeptide, fragment, or mimetic.

30 However, in order to treat precursor cells it is not necessary that the precursor cells are a pure population. Consequently, the precursor population can still be expanded

selectively. Furthermore, purification may not be necessary or desirable prior to therapeutic administration *in vivo*.

The isolation of precursor cells for use in the invention can be carried out by  
5 any of numerous methods commonly known to those skilled in the art. For example, one common method for isolating precursor cells is to collect a population of cells from a subject and using differential antibody binding, wherein cells of one or more certain differentiation stages are bound by antibodies to differentiation antigens, fluorescence activated cell sorting is used to separate the desired precursor cells  
10 expressing selected differentiation antigens from the population of isolated cells.

One type of progenitor cells used for therapeutic applications are those derived from the mesenchyme. Mesenchymal progenitors give rise to a very large number of distinct tissues (Caplan, J. Orth. Res 641-650, 1991). Most work to date involves the  
15 isolation and culture of cells which can differentiate into chondrocytes and osteoblasts. The systems developed to isolate the relevant progenitor cell populations were worked out first in chick embryos (Caplan, Exp. Cell. Res. 62:341-355, 1970; Caplan, 1981, 39th Annual Symposium of the Society for Developmental Biology, pp. 37-68; Caplan *et al.*, 1980, Dilatation of the Uterine Cervix 79-98; DeLuca *et al.*,  
20 J. Biol. Chem. 252:6600-6608, 1977; Osdoby *et al.*, Dev. Biol. 73:84-102, 1979; Syftestad *et al.*, Dev. Biol. 110:275-283, 1985). Conditions were defined under which chick mesenchymal cells differentiated into chondrocytes and bone. With regard to cartilage and bone, the properties of mouse or human mesenchymal limb appear to be quite similar if not identical (Caplan, J. Orth. Res. 641-650, 1991). Mesenchymal  
25 cells capable of differentiating into bone and cartilage have also been isolated from marrow (Caplan, J. Orth. Res. 641-650, 1991).

Caplan *et al.*, U.S. Pat. No. 5,226,914 describes an exemplary method for isolating mesenchymal stem cells from bone marrow. These isolated marrow stem  
30 cells can be used in conjunction with a TGF- $\alpha$  polypeptide, fragment, or mimetic to expand the stem cell population. These expanded cells may then be transplanted into a

subject where they can differentiate into osteocytes, cartilage, chondrocytes, adipocytes, etc., depending on the surrounding microenvironment of the transplant site. Alternatively, the expanded stem cells can be contacted *in vitro* prior to transplantation with agents which induce differentiation of the stems cells down a particular lineage.

It has been possible to purify marrow mesenchymal cells by their differential adhesion to culture dishes and demonstrate that they can differentiate, *e.g.*, into osteoblasts. Expansion of such isolated stem cells using a TGF- $\alpha$  polypeptide, fragment, or mimetic can provide a source of cells which when transplanted to the appropriate sites will be induced by the microenvironment to differentiate into the appropriate lineage and help repair damaged and/or diseased tissue. It is expected that the animal models described to date will be applicable to humans. Indeed, as far as cartilage and bone are concerned, the properties of mouse and human limb mesenchymal cells in culture are quite similar, if not identical (Hauska, Dev. Biol. 37:345-368, 1974; Owens and Solursh, Dev. Biol. 88:297-311, 1981). The isolation of human marrow and the demonstration that cells deriving from it can sustain osteogenesis has been described, *e.g.*, by Bab *et al.*, Bone Mineral 4:373-386, 1988.

Several bone marrow isolation protocols have been reported and can be used to obtain progenitor or precursor cells. Single cell suspensions from rat bone marrow can be prepared according to Goshima *et al.*, Clin. Orth. and Rel. Res. 262:298-311, 1991. Human stem cell cultures from marrow can be prepared as described by Bab *et al.*, Bone Mineral 4:373-386, 1988, as follows: Whole marrow cells are obtained from a subject. The marrow samples are separated from either the iliac crest or femoral midshaft. Marrow samples, 3 ml in volume, are transferred to 6 ml of serum-free Minimal Essential Medium (MEM) containing 50 U/ml penicillin and 0.05 mg/ml streptomycin-sulfate. A suspension of predominantly single cells is prepared as described in Bab *et al.*, Calcif. Tissue Int. 36:77-82, 1984; and Ashton *et al.*, Calcif. Tissue Int. 36:83-86, 1984, by drawing the preparation into a syringe and expelling it several times sequentially through 19, 21, 23 and 25 gauge needles. The cells are

counted using a fixed volume hemocytometer and the concentration adjusted to  $1-5 \times 10^8$  total marrow cells per ml suspension. Positive and negative control cell suspensions can be set as described in Shteyer *et al.*, Calcif. Tissue Int. 39:49-54, 1986, using rabbit whole marrow and spleen cells, respectively.

5

Adult neural precursors are generally located in the wall of the brain ventricles. It is thought that from these proliferative regions, neuronal precursors migrate towards target positions where the microenvironment induces them to differentiate. Studies have been reported where cells from the sub-ventricular zone  
10 can generate neurons both *in vivo* as well as *in vitro*, reviewed in Alvarez-Buylla and Lois, Stem Cells (Dayt) 13:263-272, 1995.

The neuronal precursors from the adult brain can be used as a source of cells for neuronal transplantation (Alvarez-Buylla, Proc. Natl. Acad. Sci. USA 90:2074-  
15 2077, 1993). Neural crest cells have also been long recognized to be pluripotent neuronal cells which can migrate and differentiate into different neuronal cell types according to the instructions they receive from the microenvironment they find themselves in (LeDouarin and Ziller, Curr. Opin. Cell Biol. 5:1036-1043, 1993). In addition, neurogenesis has been shown to occur in the hippocampus, olfactory bulb  
20 and epithelium and that endogenous neural precursors can be induced *in situ* to differentiate into mature neurons in response to signaling molecules, in regions of adult mammalian neocortex that do not normally undergo any neurogenesis (Magavi *et al.*, Nature, 405:951-955 (2000)).

25 Neural stem cells have been found in subependyma throughout the adult rodent CNS (Ray *et al.* Soc. Neurosci., 22:394.5, 1996) and in the subependyma of adult human forebrain (Kirschenbaum *et al.*, Cerebral Cortex 4:576-589, 1994). Thus, the discovery that TGF- $\alpha$  stimulates proliferation of neural stem cells and promotes migration to a site of injury or deficit has led to its investigation for the  
30 treatment of a neurodegenerative disorder (Alzheimer's Disease, Huntington's Disease and Parkinson's Disease) or CNS traumatic injury (*e.g.*, spinal chord injury),



demyelinating disease, CNS inflammatory disease, CNS autoimmune disease (*e.g.*, multiple sclerosis) and CNS ischemic disease (*e.g.*, stroke or brain attack).

5 A CNS stem cell has the potential to differentiate into neurons and astrocytes as well as self replication and thus self renewal. Both neuronal and glial cells are derived from a common precursor cell. In the vertebrate CNS, pluripotential cells have been identified *in vitro* and *in vivo*. Certain mitogens, such as TGF- $\alpha$ , can cause proliferation of CNS pluripotential cells *in vitro*. Thus, it is possible to harvest such cell from a subject, treat them *ex vivo* to stimulate proliferation in culture and then  
10 readminister the cells back to a subject. Immunohistochemical analysis in the human brain supports the notion that TGF- $\alpha$  and its 35 kD precursor are widely distributed in neurons and glial cells both during development and during adulthood. In TGF- $\alpha$  knockout mice genetically altered to lack expression of functioning TGF- $\alpha$ , there was a decrease in neural progenitor cell proliferation in forebrain subependyma,  
15 providing evidence for TGF- $\alpha$  as a proliferative factor for neural progenitor cells.

TGF- $\alpha$  is found mainly in various neurons of the CNS during development and in the adult brain in the cerebral neocortex, hippocampus and striatum. It is also found in glial cells, primarily in the cerebral and cerebellar cortex areas. Northern  
20 blot analyses showed that TGF- $\alpha$  but not EGF (epidermal growth factor) is the most abundant ligand that binds to one or more of the EGF receptor family in the brain. TGF- $\alpha$  mRNA levels were 15-170 times higher than EGF in cerebellum and cerebral cortex. TGF- $\alpha$  also appears in germinal centers of the brain during neurogenesis and gliogenesis in the developing brain. In the midbrain, the distribution of TGF- $\alpha$   
25 overlaps with tyrosine hydroxylase mRNA and fetal dopaminergic neurons. In culture, TGF- $\alpha$  enhanced survival and neurite outgrowth of neonatal rat dorsal ganglion neurons (EGF did not) and survival and differentiation of CNS neurons. TGF- $\alpha$  induced proliferation of neural precursor cells of the murine embryonic mesencephalon and further induced a significant increase in the number of astroglia  
30 and microglia in fetal rat medial septal cells. TGF- $\alpha$  increased glutamic acid

decarboxylase activity and decreased choline acetyltransferase activity. Thus, TGF- $\alpha$  acted as a general neuronal survival factor affecting both cholinergic and GABAergic neurons. In addition, TGF- $\alpha$  is a mitogen for pluripotent brain stem cells. Forebrain subependyma contains nestin positive neural stem cells and their progeny, which are constitutively proliferating progenitor epithelial cells. A “knockout” mouse that was genetically engineered to delete the gene for TGF- $\alpha$  showed a reduction in neuronal progenitor cells in the subependyma and a reduction in neuronal progenitors that migrate to the olfactory bulb. *In vitro*, TGF- $\alpha$  promoted dopamine uptake in fetal rat dopaminergic neurons in a dose-dependent and time-dependent manner. TGF- $\alpha$  selectively promoted dopaminergic cell survival, enhanced neurite length, branch number and the soma area of tyrosine hydroxylase immunopositive cells. The levels of TGF- $\alpha$  were elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s Disease and may represent a compensatory response to neurodegeneration. Further, TGF- $\alpha$  prevented a striatal neuronal degeneration in an animal model of Huntington’s Disease. Accordingly, the administration to a subject or the contacting of neuronal precursor cells *in vitro* with a TGF-  $\alpha$  polypeptide, fragment or mimetic of the invention is useful in promoting cell proliferation (including stem cell proliferation) and tissue repair in, for example, the central nervous system.

20

The fact that fetal brain tissue has been shown to have clear behavioral effects when transplanted into adult lesioned brains, has focused attention on human fetal tissue as a potential cell source in transplantation protocols designed to improve neurodegenerative disorders (Bjorklund, *Nature* 362:414-415, 1993; McKay, *Trends Neurosci.* 14:338-340, 1991). Nevertheless both ethical, as well as practical considerations make fetal tissue a difficult source to use. Expansion of neuronal stem cells whether fetal or otherwise using a TGF-  $\alpha$  polypeptide, fragment or mimetic of the invention provides an alternative source for obtaining the desired quantities of precursor cells for transplantation purposes. Fetal tissues or adult tissues containing precursors can be treated with a TGF-  $\alpha$  polypeptide, fragment or mimetic of the invention as described earlier in order to expand the undifferentiated progenitor cell

30

populations. Fetal cells can be placed into primary culture using, for example, protocols developed by Sabate *et al.*, Nature Gen. 9:256-260, 1995, before being treated with a TGF-  $\alpha$  polypeptide, fragment or mimetic of the invention. By way of example but not limitation, the procedure is as follows: Primary cultures of human fetal brain cells  
5 can be isolated from human fetuses, obtained from legal abortions after 5 to 12 weeks of gestation. Expulsion can be done by syringe-driven gentle aspiration under echographic control. Fetuses collected in sterile hibernation medium are dissected in a sterile hood under a stereomicroscope. Brains are first removed in toto in hibernation medium containing penicillin G 500 U/ml, streptomycin 100  $\mu$ g/ml, and fungizon 5  
10  $\mu$ g/ml. For fetuses of six to eight weeks of age the brain is separated into an anterior (telencephalic vesicles and diencephalon) and a posterior fraction (mesencephalon, pons and cerebellar enlage) and a posterior in toto after careful removal of meninges. For older fetuses, striatal hippocampal, cortical and cerebellar zones expected to contain proliferative precursor cells are visualized under the stereomicroscope and  
15 dissected separately. Cells are transferred to either Opti-MEM (Gibco BRL) containing 15% heat-inactivated fetal bovine serum (FBS) (Seromed), or to a defined serum-free medium (DS-FM) with human recombinant bFGF (10 ng/ml, Boehringer), which is a minor modification of the Bottenstein-Sato medium 39 with glucose, 6 g/l, glutamine 2 mM (Gibco BRL), insulin 25  $\mu$ g/ml (Sigma) transferrin 100  $\mu$ g/ml  
20 (Sigma), sodium selenite 30 nM (Gibco BRL), progesterone 20 nM (Sigma), putrescine 60 nM (Sigma), penicillin G (500 U/ml), streptomycin 100  $\mu$ g/ml, and fungizon 5  $\mu$ g/ml. Cells, approximately 40,000 per  $\text{cm}^2$ , are grown at 37 °C in an atmosphere containing 10% CO<sub>2</sub> in tissue culture dishes (Falcon or Nunc) coated with gelatin (0.25% wt/vol) followed by Matrigel (Gibco BRL, a basement membrane  
25 extract enriched in laminin and containing trace amounts of growth factors diluted one in 20). Cells in culture can be treated with a TGF-  $\alpha$  polypeptide, fragment or mimetic of the invention in order to expand the population of the appropriate cells until the desired cell mass is reached for transplantation.

30 Any technique which provides for the isolation, propagation, and maintenance *in vitro* of hematopoietic stem cells (HSC) can be used in this embodiment of the

invention. Techniques by which this can be accomplished include (a) the isolation and establishment of HSC cultures from bone marrow cells isolated from the future host, or a donor, or (b) the use of previously established long-term HSC cultures, which may be allogeneic or xenogeneic. Non-autologous HSC are used preferably in  
5 conjunction with a method of suppressing transplantation immune reactions of the future host/patient. In a particular embodiment of the present invention, human bone marrow cells can be obtained from the posterior iliac crest by needle aspiration (see, *e.g.*, Kodo *et al.*, J. Clin. Invest. 73:1377-1384, 1984). In a one embodiment of the present invention, the HSCs can be made highly enriched or in substantially pure  
10 form. This enrichment can be accomplished before, during, or after long-term culturing, and can be done by any techniques known in the art. Long-term cultures of bone marrow cells can be established and maintained by using, for example, modified Dexter cell culture techniques (Dexter *et al.*, J. Cell Physiol. 91:335, 1977) or Witlock-Witte culture techniques (Witlock and Witte, Proc. Natl. Acad. Sci. USA  
15 79:3608-3612, 1982).

Another technique for the isolation of HSC is described by Milner *et al.*, Blood 83:2057-2062, 1994. Bone marrow samples are obtained and are separated by Ficoll-Hypaque density gradient centrifugation, are washed, and stained using two-  
20 color indirect immunofluorescent antibody binding and then separated by fluorescence-activated cell sorting (FACS). The cells are labelled simultaneously with IgG antibodies such that CD34<sup>+</sup> hematopoietic stem cells, including the immature subset that lacks expression of individual lineage associated antigens, CD34<sup>+</sup> lin<sup>-</sup>, are isolated from the cells collected from marrow.

25

Where hematopoietic progenitor cells are desired, the presence of hematopoietic progenitor cells and/or their progeny can be detected by commonly known *in vitro* colony forming assays (*e.g.*, those that detect CFU-GM, BFU-E). As another example, assays for hematopoietic stem cells are also known in the art (*e.g.*,  
30 spleen focus forming assays, assays that detect the ability to form progenitors after replating).

Epithelial stem cells (ESCs) or keratinocytes can be obtained from tissues such as the skin and the lining of the gut by known procedures (Rheinwald, Meth. Cell Bio. 21A:229, 1980). In stratified epithelial tissue such as the skin, renewal occurs by mitosis of precursor cells within the germinal layer, the layer closest to the basal lamina. Precursor cells within the lining of the gut provide for a rapid renewal rate of this tissue. ESCs or keratinocytes obtained from the skin or lining of the gut of a patient or donor can be grown in tissue culture (Rheinwald, Meth. Cell Bio. 21A:229, 1980; Pittelkow and Scott, Mayo Clinic Proc. 61:771, 1986). If the ESCs are provided by a donor, a method for suppression of host versus graft reactivity (e.g., irradiation, drug or antibody administration to promote moderate immunosuppression) can also be used.

Liver stem cells can be isolated by methods described in PCT Publication WO 94/08598, dated April 28, 1994 and in U.S. Patent No. 5,559, 022 to Naughton *et al.* the disclosures of which are incorporated herein by reference.

Mammalian kidney emerges from the metanephric mesenchyme which induces the uterine bud to undergo a series of morphogenetic movements ultimately forming the mature urinary collecting system (Nigam and Brenner, Curr. Opin. Nephrol. Huper 1:187-191, 1992). The uterine bud, an epithelial outgrowth of the Wolfian duct, contracts and induces condensing adjacent mesenchyme along differentiation pathways of epithelial divergence in early embryonic life. Attempts to study this process *in vitro* have been reported; metanephros in organ culture can be induced to form tubules using embryonic spinal cord as the inducer. While the specific transducing agents that lead to the induction of metanephric mesenchyme by the uterine bud *in vivo* or by spinal cord *in vitro* are not known, it is clear that differentiation program is induced in progenitor cells (Karp *et al.*, Dev. Biol. 91:5286-5290, 1994).

30

After the precursors cells have been isolated according to the methods described above or other methods known in the art, the precursor cells can be contacted with an amount of a TGF-  $\alpha$  polypeptide, a related polypeptide, fragment or mimetic of the invention effective to promote growth and proliferation under cell growth conditions (*e.g.*, promoting mitosis) such that the cell proliferates to obtain an expanded precursor population according to the present invention.

In one embodiment, a TGF-  $\alpha$  polypeptide, related polypeptide, fragment or mimetic of the invention can be used in conjunction with factors that inhibit differentiation such as Notch (see, U.S. Patent No. 5,780,300). Under such conditions substantially no differentiation of the precursor cells would occur during expansion. The amount of differentiation that occurs can be assayed for by known assays, *e.g.*, those that detect the presence of more differentiated cells by detecting functions associated with a particular stage of differentiation, *e.g.*, expression of differentiation antigens on the cell surface or secretion of proteins associated with a particular state, or ability to generate various cell types, or detecting morphology associated with particular stages of differentiation.

Once the population has reached a desired titer, factors that allow at least some of the cells in the expanded population to differentiate can be added to the culture. Such factors can be added in order to achieve a desired differentiation state or to induce differentiation of the cells such that the cells express a desired phenotype. The cells can be differentiated to a terminally differentiated state if the function of that terminally differentiated cell is desired. Factors which promote differentiation are known in the art and include, for example, retinoic acid, dexamethasone, and dimethylsulfoxide (DMSO).

In one embodiment, the method uses a population of lymphoid stem cell progenitor cells, phenotypically characterized as CD34<sup>+</sup>. The culture medium is a standard culture medium for stem cell cultures such as a 61.2 or 62.2 medium (Counter, *EMBO J.* 11:1921, 1992) or 80% Dulbecco's modified Eagle medium (such

as high glucose with 1.0  $\mu$ M GLN, 0.1  $\mu$ M  $\beta$  mercaptoethanol and 1% nonessential amino acid stock, GIBCO-BRL) supplemented with human TGF- $\alpha$  polypeptide, fragment or a mimetic thereof at a concentration of from about 25  $\mu$ g/ml to about 100  $\mu$ g/ml. The cultures are grown up to a concentration of stem cells of about  $0.5 \times 10^5$  cells/ml to about  $5 \times 10^6$  cells/ml or more. The cells are then exposed to T cell differentiation factors (such as IL-2) for a period of about 2 days and then to an antigen for a period of about 2 to 3 days at an antigen concentration of from about 10  $\mu$ g/ml to about 100  $\mu$ g/ml. This two-stage procedure primes progenitor T cells and then mixes them with B cells. The source of the B cells can be isolated from peripheral blood (separated from T cells using standard purification procedures, such as glass wool columns of CD4<sup>+</sup> cells depleted with specific antibodies). The process "primes" the stem cells to differentiate into primed T cells. Typically, the antigen is a polypeptide or glycopeptide for an infectious disease, such as hepatitis C antigen or the gp120 protein of HIV. The cells are washed to remove antigen and the culture of predominantly primed T cells are administered back to the subject from which they were derived. In addition, primed B cells that provide a humoral (antibody) response to the antigen can also be administered.

The cells produced (*e.g.*, expanded) by use of a TGF- $\alpha$  polypeptide, related polypeptide, fragment or mimetic of the invention can be made recombinant after expansion and used in gene therapy, protein production, or protein delivery techniques. In its broadest sense, gene therapy refers to therapy performed by the administration of a nucleic acid to a subject. The nucleic acid, either directly or indirectly via its encoded protein, mediates a therapeutic effect in the subject. By protein production means that a recombinant cell produced by use of a TGF- $\alpha$  polypeptide, fragment or mimetic of the invention can be recombinantly modified to produce a protein *in vitro* for collection, administration or modification. By protein deliver means that a recombinant cell modified to produce a polypeptide of interest is administered to a subject wherein the polypeptide of interest is expressed by the cell and secreted or otherwise delivered to the subject for a therapeutic or non-therapeutic

purpose. Example of non-therapeutic purposes includes the expression of a detectable marker *in vivo*.

5 The present invention provides methods of gene therapy wherein a nucleic acid encoding a protein of therapeutic value (preferably to humans) is introduced into the precursor cells expanded according to the invention, before or after expansion, such that the nucleic acid is expressible by the precursor cells and/or their progeny, followed by administration of the recombinant cells to a subject.

10 The recombinant precursor cells of the present invention can be used in any of the methods for gene therapy available in the art. Thus, the nucleic acid introduced into the cells may encode any desired protein, *e.g.*, a protein missing or dysfunctional in a disease or disorder. The descriptions below are meant to be illustrative of such methods. It will be readily understood by those of skill in the art that the methods  
15 illustrated represent only a sample of all available methods of gene therapy.

For general reviews of the methods of gene therapy, see "The Development of Human Gene Therapy," Eds. Theodore Friedmann, Cold Springs Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1999; Goldspiel *et al.*, *Clinical Pharmacy* 12:488-  
20 505, 1993; Wu and Wu, *Biotherapy* 3:87-95, 1991; Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596, 1993; Mulligan, *Science* 260:926-932, 1993; and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217, 1993; May, 1993, *TIBTECH* 11(5):155-215). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel *et al.* (eds.), 1993, *Current Protocols in*  
25 *Molecular Biology*, John Wiley & Sons, NY; and Kriegler, 1990, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY.

In an embodiment in which recombinant precursor cells are used in gene therapy, a gene whose expression is desired in a patient or subject is introduced into  
30 the precursor cells such that it is expressible by the cells and/or their progeny, and the recombinant cells are then administered *in vivo* for therapeutic effect.



Precursor cells or expanded precursor cells can be used in any appropriate method of gene therapy, as would be recognized by those in the art upon considering this disclosure. The resulting action of a recombinant precursor cell or its progeny  
5 cells administered to a patient can, for example, lead to the activation or inhibition of a pre-selected gene in the patient, thus leading to improvement of the diseased condition afflicting the patient.

The desired gene is transferred to precursor cells in tissue culture by such  
10 methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those precursor cells are then delivered to a patient.

15 In this embodiment, the desired gene is introduced into a precursor cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector  
20 containing the gene sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see *e.g.*, Loeffler and Behr, Meth. Enzymol. 217:599-618, 1993; Cohen *et al.*, Meth. Enzymol. 217:618-644, 1993; Cline, Pharmac. Ther. 29:69-92, 1985) and may be used in accordance  
25 with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the gene to the cell, so that the gene is expressible by the cell and preferably heritable and expressible by its cell progeny.

30 One common method of practicing gene therapy is by making use of retroviral vectors (see Miller *et al.*, Meth. Enzymol. 217:581-599, 1993). A retroviral vector is

a retrovirus that has been modified to incorporate a preselected gene in order to effect the expression of that gene. It has been found that many of the naturally occurring DNA sequences of retroviruses are dispensable in retroviral vectors. Only a small subset of the naturally occurring DNA sequences of retroviruses is necessary. In  
5 general, a retroviral vector must contain all of the cis-acting sequences necessary for the packaging and integration of the viral genome. These cis-acting sequences include: a) a long terminal repeat (LTR), or portions thereof, at each end of the vector; b) primer binding sites for negative and positive strand DNA synthesis; and c) a packaging signal, necessary for the incorporation of genomic RNA into virions. The  
10 gene to be used in gene therapy is cloned into the vector, which facilitates delivery of the gene into a precursor cell by infection or delivery of the vector into the cell.

Adenoviruses and HIV-1 based lentiviral vectors are also of use in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to  
15 respiratory precursor cells. Adenoviruses can also be used to deliver genes to precursor cells from the liver, the central nervous system, endothelium, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503, 1993, present a review of adenovirus-based gene therapy. Other instances of the use  
20 of adenoviruses in gene therapy can be found in Rosenfeld *et al.*, *Science* 252:431-434, 1991; Rosenfeld *et al.*, *Cell* 68:143-155, 1992; and Mastrangeli *et al.*, *J. Clin. Invest.* 91:225-234, 1993.

In a specific embodiment, the desired gene recombinantly expressed in the  
25 precursor cell to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the recombinant gene is controllable by controlling the presence or absence of the appropriate inducer of transcription.

30 In another embodiment, if a greater number of differentiated cells is desired before administering to a patient then the precursor cells can be differentiated prior to

expansion. In another embodiment, one can expand and differentiate the precursor cells simultaneously such that greater numbers of differentiated cells are obtained.

5 The isolation of stem cells or precursor cells for use in the present invention can be carried out by any of numerous methods commonly known to those skilled in the art. For example, one common method for isolating stem cells or precursor cells is to collect a population of cells from a subject and use differential antibody binding, wherein cells of one or more certain differentiation stages are bound by antibodies to differentiation antigens, to separate the precursor or stem cells from the isolated  
10 population. Methods of separating the cells includes, for example, fluorescence activated cell sorting..

In one embodiment of the invention, epithelial stem cells or keratinocytes are obtained from tissues such as the skin and the lining of the gut by known procedures  
15 (Rheinwald, 1980, Meth. Cell Bio. 21A:229). In stratified epithelial tissue such as the skin, renewal occurs by mitosis of stem cells within the germinal layer, the layer closest to the basal lamina. Stem cells within the lining of the gut provide for a rapid renewal rate of this tissue. ESCs or keratinocytes obtained from the skin or lining of the gut of a subject can be grown in tissue culture (Rheinwald, 1980, Meth. Cell Bio.  
20 21A:229; Pittelkow and Scott, 1986, Mayo Clinic Proc. 61:771).

In another embodiment of the invention, mesenchymal progenitor cells are used in cell replacement therapy. Mesenchymal progenitor cells give rise to a very large number of distinct tissues, for example chondrocytes, osteoblasts, cartilage and  
25 bone (Caplan, J. Orth. Res. 641-650, 1991). Conditions have been defined under which chick mesenchymal cells differentiated into chondrocytes and bone. (Caplan, Exp. Cell. Res. 62:341-355, 1970; Caplan, 1981, 39th Annual Symposium of the Society for Developmental Biology, pp. 37-68; Caplan *et al.*, Dilatation of the Uterine Cervix 79-98, 1980; DeLuca *et al.*, J. Biol. Chem. 252:6600-6608, 1977; Osdoby *et al.*, Dev. Biol. 73:84-102, 1979; Syftestad *et al.*, Dev. Biol. 110:275-283, 1985).  
30 Mesenchymal cells capable of differentiating into bone and cartilage have also been

isolated from marrow (Caplan, 1991, J. Orth. Res. 641-650). Caplan *et al.*, 1993, U.S. Pat. No. 5,226,914 describes an exemplary method for isolating mesenchymal stem cells from bone marrow. Furthermore, the isolation of human marrow and the demonstration that cells deriving from it can sustain osteogenesis has been described,  
5 *e.g.*, by Bab *et al.*, Bone Mineral 4:373-386, 1988.

The mucosal epithelium of the intestine is in a continually dynamic state known as “epithelial renewal” in which undifferentiated stem cells from a proliferative crypt zone divide, differentiate and migrate to the luminal surface. Once  
10 terminally differentiated, mucosal epithelial cells are sloughed from the tips of the villi. The turnover of the crypt-villus cell population is rapid and occurs every 24-72 hours. Continuous exfoliation of the cells at the villus tip is counterbalanced by ongoing proliferation in the crypt so that net intestinal epithelial mass remains relatively constant. The rapidly-proliferating epithelium of the gastrointestinal tract is  
15 extremely sensitive to cytotoxic drugs that are widely used in cancer chemotherapy. By “gastrointestinal tract” is meant, for example, the tissues of the mouth, esophagus, stomach, small intestine, large intestine, rectum and anus. This “side effect” reduces the tolerated dose of such drugs as it can cause a breakdown of the GI barrier function and septic propagate a septic condition in a patient already immuno-compromised.  
20 This can also lead to life-threatening hemorrhage. Therefore, there is a need in the art for the development of products and delivery systems that stimulate the repair and rejuvenation of mucosal epithelium in the gastrointestinal tract to provide benefit to subjects having, for example, weight-loss disorders associated with chemotherapy and radiation therapy for cancer as well as disorders or diseases associated with pathogens  
25 such as HIV.

The replacement cells of the present invention can be transplanted into a patient for the treatment of disease or injury or for gene therapy by any method known in the art which is appropriate for the type of stem cells being transplanted and  
30 the transplant site. Hematopoietic stem cells can be transplanted intravenously, as can

liver stem cells which will locate to the liver. Neural stem cells can be transplanted directly into the brain at the site of injury or disease.

The following describes exemplary methods which can be modified for the  
5 transplantation of replacement cells: Protocols for the isolation and transplantation of fetal tissues in humans have been reported and clinical trials involving these studies having been carried out. For example, Lindvall *et al.*, Science 247:574-577, 1990, have described results regarding grafts and survival of fetal dopamine neurons after transplantation into brain. Rinsing and partial dissociation of precursor cells, if  
10 necessary, can be carried out by a modification of that described in Lindvall *et al.*, Arch. Neurol. 46:615, 1989.

By way of example, implantation of cells into the brain can be performed as follows. Implantation is done at three sites in the left putamen with a stereotactic  
15 technique (Lindvall *et al.*, Arch. Neurol. 46:615, 1989). For each site, 20  $\mu$ l of the dissociated cells is drawn into the instrument (outer diameter, 1.0 mm). The cells are injected along a 10, 12 and 14 mm linear tract, respectively, in either 2.5  $\mu$ l portions for 15 to 20 seconds each. Between each injection there is a 2 minute delay, and the cannula is then retracted 1.5 to 1.7 mm. After the final injection, the cannula is left *in*  
20 *situ* for 8 minutes before being slowly withdrawn from the brain. After surgery the cell viability is assessed following the procedure of Brundin *et al.*, Brain. Res. 331:251, 1985.

Another example is outlined by Caplan *et al.*, 1993, U.S. Pat. No. 5,226,914.  
25 Briefly, after marrow cells are harvested from bone marrow plugs and the marrow mesenchymal, stem cells are separated by centrifugation. The stem cells are isolated further by selective adherence to the plastic or glass surface of a tissue culture dish. The stem cells are allowed to proliferate, but not differentiate. Porous ceramic cubes composed of 60% hydroxyapatite and 40%  $\beta$ -tricalcium phosphate are added to the  
30 cells under a slight vacuum. The cubes with adhered cells are implanted into

incisional pockets along the backs of nude mice. The mesenchymal stem cells differentiate into bone.

5 The titer of stem cells transplanted or the amount of a therapeutic which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, *in vitro* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder,  
10 and should be decided according to the judgment of the practitioner and each patient's circumstances.

The precursor cells to be expanded in the present invention can be isolated from a variety of sources using methods known to one skilled in the art as described  
15 above, and can be of any animal, preferably mammalian, most preferably human, and can be of primary tissue, cell lines, etc.

The TGF- $\alpha$  polypeptides (*e.g.*, SEQ ID NO:1), TGF- $\alpha$  fragments and mimetics thereof are particularly suited for delivery to a subject by means of a nucleic acid gene  
20 expression system *ex vivo* or *in vivo*. A variety of transfection techniques are currently available and used to transfer DNA *in vitro* into cells; including calcium phosphate-DNA precipitation, DEAE-Dextran transfection, electroporation, liposome mediated DNA transfer or transduction with recombinant viral vectors. Such *ex vivo* treatment protocols have been used to transfer DNA into a variety of different cell  
25 types including epithelial cells (U.S. Pat. No. 4,868,116; Morgan and Mulligan WO87/00201; Morgan *et al.*, Science 237:1476-1479, 1987; Morgan and Mulligan, U.S. Pat. No. 4,980,286), endothelial cells (WO89/05345), hepatocytes (WO89/07136; Wolff *et al.*, Proc. Natl. Acad. Sci. USA 84:3344-3348, 1987; Ledley *et al.*, Proc. Natl. Acad. Sci. 84:5335-5339, 1987; Wilson and Mulligan,  
30 WO89/07136; Wilson *et al.*, Proc. Natl. Acad. Sci. 87:8437-8441, 1990) fibroblasts (Palmer *et al.*, Proc. Natl. Acad. Sci. USA 84:1055-1059, 1987; Anson *et al.*, Mol.

Biol. Med. 4:11-20, 1987; Rosenberg *et al.*, Science 242:1575-1578, 1988; Naughton & Naughton, U.S. Pat. No. 4,963,489), lymphocytes (Anderson *et al.*, U.S. Pat. No. 5,399,346; Blaese, R. M. *et al.*, Science 270:475-480, 1995) and hematopoietic stem cells (Lim, B. *et al.* Proc. Natl. Acad. Sci. USA 86:8892-8896, 1989; Anderson *et al.*,  
5 U.S. Pat. No. 5,399,346). A summary of typical protocols, methodology, and vectors is provided in "The Development of Human Gene Therapy," Ed. Theodore Friedmann, Cold Spring Harbor Laboratory Press, New York, 1999, the disclosure of which is incorporated herein.

Direct *in vivo* gene transfer has recently been attempted with formulations of  
10 DNA trapped in liposomes (Ledley *et al.*, J. Pediatrics 110:1, 1987); or in proteoliposomes that contain viral envelope receptor proteins (Nicolau *et al.*, Proc. Natl. Acad. Sci. U.S.A. 80:1068, 1983); and DNA coupled to a polylysine-glycoprotein carrier complex. In addition, "gene guns" have been used for gene delivery into cells (Australian Patent No. 9068389). Naked DNA, or DNA associated  
15 with liposomes, can be formulated in liquid carrier solutions for injection into interstitial spaces for transfer of DNA into cells (Felgner, WO90/11092).

As described above, polynucleotide sequences encoding a TGF- $\alpha$  polypeptide or function peptide fragment or mimetic, can be cloned into vectors suitable for delivery to host cells for expression. In particular retroviral vectors containing the  
20 polypeptides of the invention are particularly suitable for delivering polynucleotides to cells for gene therapy. Current strategies for gene therapy are reviewed in "The Development of Human Gene Therapy," Ed. Theodore Friedmann, Cold Spring Harbor Laboratory Press, New York, 1999, the disclosure of which is incorporated herein.

25 Delivery of a polynucleotide of interest may be accomplished *in vivo* by administration of the vectors to an individual subject, typically by systemic administration (*e.g.*, intravenous, intraperitoneal, intramuscular, subdermal, or intracranial infusion). Alternatively, the vectors may be used to deliver polynucleotides to cells *ex vivo* such as cells explanted from an individual patient

(*e.g.*, tumor-infiltrating lymphocytes, bone marrow aspirates, tissue biopsy) or universal donor hematopoietic stem cells, followed by reimplantation of the cells into a patient, usually after selection for cells which have incorporated the polynucleotide.

5 The vectors may be used for gene therapy to reduce the incidence of weight-loss and associated disorders resulting from particular diseases (*e.g.*, cancer), or viral diseases (*e.g.*, AIDS, mononucleosis, herpesvirus infection, cytomegalovirus infection, papillomavirus infection) or to modify the genome of selected types of cells of a patient for any therapeutic benefit.

10 The vectors of the invention can be used to introduce polynucleotides into a variety of cells and tissues including myeloid cells, bone marrow cells, lymphocytes, hepatocytes, fibroblasts, lung cells, epithelial cells and muscle cells. For example, polynucleotides encoding a TGF- $\alpha$  polypeptide may be transferred to stem cells.

Mast cell degranulation often is a precursor to acute gastrointestinal injury and to an infla  
(SCF), reserpine and polymixin B), induce gastrointestinal mucosal injury and result  
15 in severe hemorrhage and tissue necrosis. In addition, administration of mast cell stabilizers, such as sodium cromoglycate, inhibited gastric mucosal injury induced by ethanol and aspirin. (Kalia and Bandhan, *J. Gastroenterolgy Hep.*, 13:1081-1083, 1998) Repeated degranulation of mast cells induces gastric mucosal injury by a mechanism dependent on nitric oxide (NO) generation. Selective inhibition of the  
20 inducible NO synthesis (NOS) by compounds, such as dexamethasone and aminoguanidine, suggested the NOS:NO system as the target mechanism. Mast cell mediators include pro-inflammatory cytokines or agents such as histamine, serotonin, prostanoids, platelet activating factor, leukotrienes B and C, and pro-inflammatory cytokines IL-1, IL-6 and TNF $\alpha$ .

25

TGF- $\alpha$  polypeptide, fragments, and mimetic provide mast cell protection from degranulation in cisplatinum-treated mice. Therefore, in view of the relationship between mast cell degranulation and mucosal toxicity, a TGF- $\alpha$  polypeptide, fragments, and mimetic reduce mast cell degranulation and thus prevent mucosal



toxicity after exposure to agents that degranulate mast cells and the pro-inflammatory cytokines causing an inflammatory reaction in reaction to mast cell products. Such mast cell products include the cytokines IL-1, IL-6 and TNF $\alpha$ . Accordingly, in view of the effects of a TGF- $\alpha$  polypeptide, fragments, and mimetic on mast cells, such  
5 therapeutic agents have a generalized anti-inflammatory activity.

The present invention further provides a method for protection of tissue or organs damaged or likely to be damaged by a cytotoxic agent (including radiation), wherein the organ or tissue is selected from the group consisting of kidney, intestine,  
10 pancreas, brain and lung, comprising administering an effective amount of a TGF- $\alpha$  polypeptide, fragments, and mimetic to the damaged tissue.

The invention also provides methods of modulating weight-loss associated with disease and disorders of the gastrointestinal tract, for example, those associated  
15 with viral infections and chemotherapy by administering TGF- $\alpha$  or related polypeptides or fragments thereof which retain TGF- $\alpha$  biological activity (*e.g.*, SEQ ID NO:1, 2, or 3, and the peptides of formula I, II, or III).

The invention further provides a pharmaceutical composition comprising a  
20 peptide in a pharmaceutically acceptable carrier, wherein the peptide compound comprises at least about a 10 to 18-membered peptide compound of formula I (SEQ ID NO:4, including members of SEQ ID NO:5 attached to SEQ ID NO:4 and including SEQ ID NO:6). Preferably, at least one or more of the seven amino acids of formula II are added to the C terminus Cys moiety. Most preferably, the functional  
25 peptide is 18 amino acids in length wherein X<sub>1a</sub> is Val, X<sub>1b</sub> is Gly, X<sub>1c</sub> is Ala and X<sub>4</sub> is Gly. The peptides described herein are all useful in the methods of the invention.

The invention further provides a bifunctional compound that acts as a TGF $\alpha$  mimetic, comprising a compound of formula III:  
30

Loop peptide N-terminus -linker-cyclic  $C_4H_8N_2$ -linker-Loop peptide N-terminus  
(VII)

wherein the linker moiety is designed to link the N-terminus of the Loop peptide to a  
5 nitrogen atom of the ring  $C_4H_8N_2$  and wherein the "loop peptide" comprises at least  
an 11-membered peptide compound of formula II:

$NH_2$ -  $X_{1a}$  - Cys - His - Ser -  $X_{1b}$  -  $X_2$  -  $X_{1a}$  -  $X_{1b}$  -  $X_{1a}$  -  $X_3$  - Cys  $COOH$  (II)

10 wherein  $X_{1a}$  and  $X_{1b}$  are independently Val, Gly or Ala;  $X_2$  is Tyr or Phe;  $X_3$  is Arg or  
Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-  
amino acid functional peptide having TGF- $\alpha$  activity. Preferably, at least one or more  
of the following amino acids are added to the C terminus Cys moiety from formula  
III:

15  
 $-X_4$  - His -  $X_{1c}$  -  $X_4$  -  $X_5$  -  $X_6$  -  $X_{1c}$  (III)

wherein  $X_4$  is Glu or Asp, wherein  $X_5$  is Leu or Ile, and wherein  $X_6$  is Asp or Glu.  
Preferably,  $X_{1a}$  is Val,  $X_{1b}$  is Gly and  $X_{1c}$  is Ala. Preferably, the linker group is  
20 independently selected from the group consisting of substituted or unsubstituted  $C_{1-6}$   
alkyl, substituted or unsubstituted  $C_{2-6}$  alkenyl, substituted or unsubstituted  $C_{1-6}$   
alkoxy, xylenyl, wherein the substitutions are selected from the group consisting of  
oxo, epoxy, hydroxyl, chloryl, bromyl, fluoryl, and amino. Preferably,  $X_2$  is Tyr, and  
 $X_3$  is Arg. Most preferably, the functional peptide is 18 amino acids in length  
25 wherein  $X_{1a}$  is Val,  $X_{1b}$  is Gly,  $X_{1c}$  is Ala and  $X_4$  is Gly.

The invention will now be described in greater detail by reference to the  
following non-limiting examples.

### **EXAMPLE 1**

Each of the three loop regions in human TGF $\alpha$  was investigated for TGF $\alpha$ -like biological activity, such as stimulation of cellular proliferation as measured by  $^3\text{H}$  thymidine incorporation of stem cells. As shown in Figure 2, only the Loop C peptide  
5 (corresponding to amino acids 33-50) showed significant TGF- $\alpha$  biological activity as compared to data obtained with TGF- $\alpha$  50 amino acid polypeptide or even the altered splice 57 amino acid polypeptide and is therefore a TGF- $\alpha$  mimetic peptide. Accordingly, data from TGF $\alpha$  or TGF- $\alpha$ 57 show what can be called "TGF- $\alpha$  activity" and that these are predictive of activity of the functional TGF- $\alpha$  peptide and similar  
10 functional TGF- $\alpha$  peptides embodied in the genus of formula I with or without the addition of a "tail" region of formula II. These data predict activity for the functional TGF- $\alpha$  peptides when activity is also shown for TGF- $\alpha$  or for TGF- $\alpha$ 57.

### **EXAMPLE 2**

#### 15 **Hematopoiesis**

TGF- $\alpha$  and related polypeptides, such as TGF- $\alpha$ 57, showed surprising enhancing activity in an *in vivo* model of general hematopoiesis when administered in conjunction with a potent cytotoxic agent Cis Platinum (CP). Figure 3 shows a graph of mouse spleen weights that were treated with CP at either 5 mg/kg or 10 mg/kg and  
20 with TGF- $\alpha$ 57 at concentrations of 10  $\mu\text{g/kg}$  or 50  $\mu\text{g/kg}$ . These data show that TGF- $\alpha$ 57 treatment caused a return to normal spleen weights despite CP treatment that reduced spleen weights significantly. This *in vivo* experiment is a predictive model for hematopoiesis in humans as CP is a cytotoxic agent commonly used for cancer chemotherapy that is known to significantly reduce trilineage hematopoietic cells.  
25 Hematopoietic and myeloid cells are red blood cell precursors, platelet precursors (megakaryocytes), and immune (white) blood cell precursors of various forms of T cells, B cells and macrophages. Moreover, platelet counts were higher in those mice injected with TGF- $\alpha$ 57 (and CP) as opposed to CP alone were such counts were significantly reduced from normal. It should be noted that references to TGF- $\alpha$  as a

human 50 amino acid polypeptide further include reference to human TGF $\alpha$ 57 as an alternative variant.

5       The experiment procedure dosed those animals to be treated with TGF $\alpha$  57 4 hours prior to challenge with CP. A single dose of CP was administered. Additional doses (as indicated) of TGF $\alpha$  57 were made at 24 hours, 48 hours, 72 hours and 96 hours after the CP dose. All doses were made by IP injection. Controls were dosed with saline instead of either or both of CP and TGF- $\alpha$ 57.

10       The animals were sacrificed about 4 hours after the last TGF- $\alpha$ 57 (or saline) dose. Key organs were removed and spleens were immediately weighed after a clean incision. All the relevant organs were placed in formalin, transported for histopathological analysis, mounted, sectioned, stained and observed. The results of this histological analysis of the spleens for hematopoietic effect and the GI tract  
15 (below) provided surprising and unexpected data of the effect of TGF- $\alpha$ 57 activity.

H&E-stained spleens of a CP-treated mouse spleen (10 mg/kg) showed apoptotic cells (densely stained with fragments of nuclei) in the germinal center (GC). T cells in the central arterial area showed the absence of a marginal zone and much  
20 fewer erythrocytes and T cells in the perifollicular area. A normal mouse spleen (no CP and no TGF- $\alpha$ 57) fixed in formalin showed an arteriole enriched for T cell progenitors. There was erythrocytes in the perifollicular zone surrounding both the T cell and B cell compartments of white pulp. A mouse spleen treated with CP (10 mg/kg) and TGF- $\alpha$ 57 (50  $\mu$ g/kg) showed an increased number of T cells and  
25 erythrocytes in the perifollicular zone. The T cells stained for the T-cell receptor but were negative for CD4 and CD8 markers. Accordingly, the T-cells are double null T-cell progenitors induced by TGF- $\alpha$  administration.

30       These *in vivo* data in a predictive model of hematopoiesis and confirmed by blinded histological analysis (the histologist/pathologist was blinded as to the treatment history of the coded tissues received) providing surprising evidence of the

utility of peptides having TGF- $\alpha$  activity to augment hematopoiesis and genesis of immune cells following cytotoxic exposure. These data predict and provide a reasonable correlation that TGF- $\alpha$  and the peptides of formula I, formula II and formula III are useful therapeutic agents for enhancing hematopoiesis following or during cytotoxic therapy, such as cancer treatment. Therefore, a useful method for improving cancer chemotherapy is to combine either TGF- $\alpha$  or a peptide from formula I, II, III, IV, V, or VI or combinations thereof with cytotoxic treatment regimens to reduce dose-limiting side effects of cytotoxic agents.

An additional experiment investigated TGF- $\alpha$  activity (using TGF- $\alpha$ 57) on human bone-marrow enriched CD34 cells. FACS-sorted human CD34 positive and CD38 negative cells were cultured in liquid primary cultures in Iscove's modified Dulbecco's media with supplements. TGF $\alpha$  (57) was added alone (10 ng/ml) and exhibited a 35% increase in CD34 positive progenitor cells. Stem Cell Factor (SCF) was used as a positive control (500 ng/ml) and provided a three-fold increase in CD34 positive cells. When a combination of SCF (500 ng/ml) and TGF $\alpha$  (10 ng/ml) was added, a synergistic 12-fold increase in CD34 positive cells was observed. An unexpected result was the stimulation of the proliferation of dendritic precursor cells in the TGF- $\alpha$  treated cultures.

20

### **EXAMPLE 3**

#### **Mucositis and Gastrointestinal Diseases**

The small intestine comprises the duodenum, jejunum and ileum. It is the principal site for absorption of digestive products from the GI tract. Digestion begins in the stomach and is completed in the small intestine in association with the absorptive process. The intestinal mucosa surface is made up of numerous finger-like projections called villi. In addition, mucosal epithelium between the basis of the villi is formed into the crypts which contain stem cells.

TGF $\alpha$  or a peptide from formula I, formula II, formula III, formula IV, formula V, or formula VI having TGF $\alpha$  activity or combinations thereof are also

useful for treating mucositis associated intestinal bleeding, dyspepsia caused by with cytotoxic therapy and for improving the barrier function of the GI tract compromised by cytotoxic therapy. The *in vivo* experiment with seven groups of mice described above for hematopoietic effects noted in spleens also examined the GI tract of these  
5 treated mice. Histological examination of mouse intestines showed the following: CP (single ip dose of 10 mg/kg) treated intestine, when cross-sectioned, showed significant injury to the villi. Specifically, the villi are necrotic, the crypts are in irregular shapes, and the tips of the crypts were exhibiting loss of cellular integrity. A cross section of a normal mouse GI tract (no CP and no TGF $\alpha$ 57) showed a normal  
10 intestinal surface with villi having long and slender mucosal projections with a core of lamina propria covered by a luminal epithelial layer. A single row of intestinal crypt is found at the base of the mucosa. These crypts that lie between adjacent villi are surrounded by the same lamina propria that form the villous cores. Both columnar absorptive cells and goblet cells cover the villous surfaces. The goblet cells contain  
15 apical clear vacuoles. A cross section of a mouse intestine exposed to both the CP (10 mg/kg) and TGF $\alpha$ 57 (50  $\mu$ g/kg) showed that the intestinal structure was very similar to the normal intestinal structure. Specifically, the villus was long and slender. Both absorptive cells and goblet cells were visible at the surface of the villi, and there was an abundant amount of goblet cells on the surface.

20

A 160X magnification of the intestines of a CP-treated mouse, a normal mouse and a CP treated and TGF $\alpha$ 57 treated mouse at the same doses as described above. The CP-treated mouse showed injured villi with degenerating and necrotic tips. Red blood cells were observed in the damaged villi. The crypts were irregularly  
25 shaped and in had various heights. The normal mouse showed smooth villi tips of the villi and nuclei of enterocytes were observed throughout the villus. The crypts were similar in height and had a regular shape. The CP treated and TGF- $\alpha$  treated mouse had normal appearing villi as described for the normal mouse. The crypts also appeared normal.

30

Further CP (10 mg/kg) treated without TGF- $\alpha$ 57 mice and CP (10 mg/kg) and 50  $\mu$ g/kg of TGF- $\alpha$ 57 treated mice intestines when examined under higher magnification showed severely injured crypt surfaces in the CP treated mice due to cell death and necrosis. Red cells were visible at the damaged surface indicating intestinal bleeding. In addition, the CP-treated mouse showed a loss of brush borders and very little of a glycocalyx or fuzzy coat. Globlet cells appeared interspersed, necrotic and fewer in number than normal. The effect of TGF- $\alpha$  treatment showed protection of the villa surface. Specifically, the epithelial cells appeared normal with extended brush borders. The nuclei were very densely stained and elongated.

10

The histological data is summarized in Figure 4 that measured average crypt height of the three groups of mice. TGF $\alpha$ 57 and TGF- $\alpha$  (50 a.a.) treatment (50  $\mu$ g/kg) was able to more-than-restore crypt height loss from CP treatment.

15

An alcian blue staining method permitted differentiation of absorptive cells and goblet cells. Goblet cell mucus is stained a blue color while the absorptive cells remain less stained. Stains of intestine from normal mice, CP only treated (10 mg/kg) and both CP (10 mg/kg) and TGF $\alpha$ 57 (50  $\mu$ g/kg) treated mice showed significant differences. In the normal intestine each villus extended from the luminal surface to the basal muscularis mucosal surface. Goblet cells were scattered and predominated in the base of the villus whereas columnar absorptive cells lined the luminal surface. In the CP treated mouse, the alcian blue staining showed villi that contained fewer number of goblet cells (than normal). The injured absorptive and goblet cells were degenerating at the tip of the villi and abundant secretory mucus material was stained in the luminal surface. In the CP/TGF- $\alpha$  mouse, there were an increased number of goblet cells scattered throughout the villi. The intestinal villi appeared normal with elongation. The majority of enterocytes did not appear to be alcian blue stained positive. The luminal plasma membranes of the villi were well protected by TGF- $\alpha$  treatment. The number of goblet cells was counted on the average unit length of intestine. TGF $\alpha$  treatment not only increased the number of goblet cells but also increased the number from CP treatment to a higher level than normal intestine.

20

25

30

Accordingly, these data show the effects of TGF $\alpha$ , and the functional peptides having TGF- $\alpha$  activity from formula I, formula II, formula III, and formula IV having therapeutic activity to treat or prevent mucositis associated with cytotoxic drug therapy and for inflammatory bowel diseases. Moreover, the histological effect showing that there was a prevention of mast cell degranulation, provides additional data supporting the gastrointestinal applications for TGF $\alpha$ , and the functional peptides having TGF- $\alpha$  activity of formula I, formula II, formula III, and formula IV.

10

#### **EXAMPLE 4**

##### **Immune Related Diseases**

In addition, TGF- $\alpha$  activity resulted in stimulation of proliferation of select immune cells (particularly of the T cell lineage) after administration to mice after immune-suppression of CP administration. The stimulated immune cells were phenotypically identified as CD4 positive T cells and double null CD4 negative CD8 negative T cell progenitors. Thus, TGF- $\alpha$  activity (*e.g.*, from TGF $\alpha$ 57 administration) resulted in generation of T-cells with characteristics that regulated immune functions. Therefore, these data predict that TGF $\alpha$  activity and the functional peptides of formula I, formula II, formula III, and formula IV will be effective in treating autoimmune diseases by mitigating over-inflammatory reactions. The *in vivo* activity of TGF $\alpha$  (and the functional peptides of formula I, formula II, formula III, and formula IV) to stimulate early T cell progenitors in the release of TH-1 and TH-2 cytokines and this regulation of immune phenomena. The stimulation of select immune cells, in particular cells of a T cell lineage, was seen consistently in the mice who received CP and TGF- $\alpha$ 57 in lymphoid tissue, Peyer's Patches and the spleen. Further, recruitment of help via CD4 cells in some cases boosts immune system function in general.



TGF- $\alpha$  administration prevented mast cell degranulation and subsequent histamine release. In addition TGF- $\alpha$  has effects in downregulating TNF- $\alpha$  receptors *in vivo* and downregulating IL-6 and MIP *in vivo*, including blocking neutrophil trafficking. This is a parallel activity that is in addition to the gastrointestinal anti-inflammatory activity and prevention of mucositis of TGF $\alpha$  (and the functional peptides of formula I, formula II, formula III, and formula IV) described herein.

5

### **EXAMPLE 5**

In order to determine the effects of TGF- $\alpha$  polypeptides on weight-loss four groups of rats were tested. The experiment was designed to compare two of the peptides of TGF- $\alpha$  (SEQ ID NO:1 and SEQ ID NO:3) on weight-loss in the presence of a  
5 chemotherapeutic drug, cisplatin.

All animals were dosed over a period of 5 days. Group 1 animals received cisplatin at 10 mg/kg, Group 2 animals received cisplatin at 10 mg/kg plus TGF- $\alpha$  (SEQ ID NO:1) at 50  $\mu$ g/kg; Group 3 animals received cisplatin at 10 mg/kg plus TGF- $\alpha$ 57 (SEQ ID NO:3) at 50  $\mu$ g/kg; and Group 4 animals received TGF- $\alpha$  (SEQ ID NO:1) at 50  
10  $\mu$ g/kg. Following completion of the dosing protocols animals from each group were measure and organs/tissues were harvested and placed in buffered formalin. The tissues measured included lungs, spleens, kidneys, pancreas, intestines and tongues.

In the 9 animals in group 1 (cisplatin treatment), the average weight loss was 18.3%; in the 13 animals in groups 2 and 3 (cisplatin+TGF) the average weight loss was  
15 12.1%; and in the 6 animals in group 4 (TGF alone) the average weight loss was 0.9% (Figure 5).

In addition, studies of TGF- $\alpha$  for the treatment of diarrhea in non-human primates was also performed. A 6-year old non-human primate exhibiting chronic inflammatory-like gastrointestinal symptoms was treated with TGF- $\alpha$  at 300  $\mu$ g/kg  
20 intraperitoneally once and subsequently 50  $\mu$ g/kg S.C. for 6 days. The primate showed a steady increase in stool consistency and the monkey showed steady weight gain through the treatment period (see Table 1 and 2). This weight gain was maintained at least for several weeks post treatment. In addition, the reduction of SEGs (see column 6, Table 1) neutrophils correlates with reduction in inflammation associated with neutrophil influx  
25 and concomitant pro-inflammatory cytokines. No adverse effects were noted in hematology or serum chemistries, or in the primates attitude, behavior or appetite.

TABLE 1

Time	wr.	hemoglobin	pcv %	wbc	Seg	Bands	Lymph	Monos	Eos	Basos	Abn. Cells	Platelets	CD4 <sup>+</sup>	CD8 <sup>+</sup>	DualCD8 <sup>+</sup> CD4 <sup>+</sup>
1	5.80	12.6	40.3	16.6	76%	0%	19%	5%	0%	0%	0%	543	28.4%	56.3%	6.7%
2	6.33	11.1	38.0	20.2	69%	0%	20%	10%	1%	0%	0%	567			
3	6.74	9.2	32.1	10.3	61%	0%	34%	4%	1%	0%	0%	456	36.7%	53.1%	6.3%
4	8.21	10.3	34.2	8.4	48%	0%	42%	9%	1%	0%	0%	534	31.3%	54.0%	9.1%
5	8.93	10.8	37.1	11.2	46%	0%	45%	8%	0%	1%	0%	425	33.4%	49.8%	8.1%
6	9.42	11.5	38.1	15.5	56%	1%	31%	11%	1%	0%	0%	434	35.1%	50.3%	7.7%

TABLE 2

Time	Na <sup>+</sup>	K <sup>+</sup>	Cl <sup>-</sup>	Glucose	BUN	Creatinine	Total Protein	Albumin	Albumin corrected	Total Bilirubin	Ca <sup>2+</sup>	Alk Phos	ALT (GPT)	AST (GOT)	GGT
1	133	3.3	87	73	45	0.6	8.6	4.9	5.9	1.2	11.6	103	8	26	57
2	144	4.8	95	51	19	0.5	7.4	3.7	4.4						
3	146	4.6	107	68	16	0.5	7.2	2.9	3.5	0.3	9.8	116	17	45	89
4	150	4.4	107	50	19	0.7	7.1	2.9	3.5	0.3	9.7	130	25	34	91
5	148	4.0	108	25	18	0.6	6.6	2.5	3.0	0.2	9.1	107	19	37	64
6	145	3.8	108	21	22	0.5	7.0	2.5	3.0	0.3	9.3	113	15	34	58

Note: Blood glucose levels are generally well below the normal reference range. This is not an abnormality. Albumin results require a correction factor for non-human primates, which is calculated into the second "Albumin corrected" column.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

## WHAT IS CLAIMED IS:

1. A method for protection of a tissue or an organ from damage by a cytotoxic agent comprising administering an effective amount of a TGF- $\alpha$  polypeptide (SEQ ID NO:1), a TGF- $\alpha$  related polypeptide, a TGF- $\alpha$ 57 polypeptide (SEQ ID NO:3), a functional fragment thereof or a mimetic thereof to the tissue or organ prior to, simultaneously with or subsequent to contacting the tissue or organ with the cytotoxic agent.
2. The method of claim 1, wherein the organ or tissue is selected from the group consisting gastrointestinal tissue, urogenital tissue, musculoskeletal tissue, nerve tissue, or cardiovascular tissue.
3. A method for treating, regenerating or repairing a tissue of a subject *in vivo*, comprising:  
contacting a tissue with a TGF-  $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a fragment or a mimetic thereof prior to, contemporaneously with, or subsequent to a tissue injury in an amount effective to induce stem cell or precursor cell proliferation, migration, or differentiation at the site of injury thereby treating, regenerating or repairing the tissue.
4. The method of claim 3, wherein the contacting is by continuous infusion of the TGF-  $\alpha$  polypeptide, fragment or mimetic.
5. The method of claim 3, wherein the contacting is by a bolus or single administration of the TGF-  $\alpha$  polypeptide, fragment or mimetic.
6. The method of claim 4, wherein the tissue is a musculoskeletal tissue, a gastrointestinal tissue, or a urogenital tissue.

7. The method of claim 5, wherein the tissue is selected from the group consisting of a musculoskeletal tissue, a gastrointestinal tissue, a urogenital tissue, and a neurological tissue.
8. The method of claim 3, wherein the stem cell is an adult stem cell.
9. The method of claim 3, wherein the stem cell is a tissue specific precursor cell.
10. The method of claim 3, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:1.
11. The method of claim 3, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.
12. The method of claim 3, wherein the polypeptide has a sequence NH<sub>2</sub>-X<sub>1a</sub> - Cys - His - Ser - X<sub>1b</sub> - X<sub>2</sub> - X<sub>1a</sub> - X<sub>1b</sub> - X<sub>1a</sub> - X<sub>3</sub> - Cys COOH (SEQ ID NO:4) wherein X<sub>1a</sub> and X<sub>1b</sub> are independently Val, Gly or Ala; X<sub>2</sub> is Tyr or Phe; X<sub>3</sub> is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- $\alpha$  activity.
13. The method of claim 12, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X<sub>4</sub> - His - X<sub>1c</sub> - X<sub>4</sub> - X<sub>5</sub> - X<sub>6</sub> - X<sub>1c</sub> (SEQ ID NO:5) wherein X<sub>4</sub> is Glu or Asp; X<sub>5</sub> is Leu or Ile; and X<sub>6</sub> is Asp or Glu.
14. The method of claim 13, wherein X<sub>1a</sub> is Val, X<sub>1b</sub> is Gly and X<sub>1c</sub> is Ala.
15. The method of claim 13, wherein X<sub>2</sub> is Tyr and X<sub>3</sub> is Arg.

16. The method of claim 13, wherein the functional peptide is 18 amino acids in length wherein  $X_{1a}$  is Val,  $X_{1b}$  is Gly,  $X_{1c}$  is Ala and  $X_4$  is Gly.
17. The method of claim 3, wherein the TGF- $\alpha$  related polypeptide is selected from the group consisting of vaccinia growth factor, amphiregulin precursor, betacellulin precursor, heparin binding EGF-like growth factor, epiregulin, HUS 19878, myxomavirus growth factor (MGF), Shope fibroma virus growth factor (SFGF), and schwannoma derived growth factor.
18. The method of claim 3, wherein the tissue injury results from cytotoxic or immune-suppressing therapy.
19. The method of claim 3, wherein the injury results from ARC or AIDS.
20. The method of claim 3, wherein the subject is a mammal.
21. The method of claim 20, wherein the mammal is a human.
22. The method of claim 3, wherein the contacting is at the site of tissue injury.
23. A method for treating, inhibiting or preventing mucositis of the gastrointestinal tract in a subject comprising administering a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a TGF- $\alpha$ 57 polypeptide, a fragment thereof, or a mimetic thereof in an amount effective to treat, inhibit or prevent gastrointestinal mucositis in the subject.
24. The method of claim 23, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:1.



25. The method of claim 23, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.
26. The method of claim 23, wherein the polypeptide has a sequence NH<sub>2</sub>-X<sub>1a</sub> - Cys - His - Ser - X<sub>1b</sub> - X<sub>2</sub> - X<sub>1a</sub> - X<sub>1b</sub> - X<sub>1a</sub> - X<sub>3</sub> - Cys COOH (SEQ ID NO:4) wherein X<sub>1a</sub> and X<sub>1b</sub> are independently Val, Gly or Ala; X<sub>2</sub> is Tyr or Phe; X<sub>3</sub> is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- $\alpha$  activity.
27. The method of claim 26, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4:  
- X<sub>4</sub> - His - X<sub>1c</sub> - X<sub>4</sub> - X<sub>5</sub> - X<sub>6</sub> - X<sub>1c</sub> (SEQ ID NO:5) wherein X<sub>4</sub> is Glu or Asp; X<sub>5</sub> is Leu or Ile; and X<sub>6</sub> is Asp or Glu.
28. The method of claim 27, wherein X<sub>1a</sub> is Val, X<sub>1b</sub> is Gly and X<sub>1c</sub> is Ala.
29. The method of claim 27, wherein X<sub>2</sub> is Tyr and X<sub>3</sub> is Arg.
30. The method of claim 27, wherein the functional peptide is 18 amino acids in length wherein X<sub>1a</sub> is Val, X<sub>1b</sub> is Gly, X<sub>1c</sub> is Ala and X<sub>4</sub> is Gly.
31. The method of claim 23, wherein the TGF- $\alpha$  related polypeptide is selected from the group consisting of vaccinia growth factor, amphiregulin precursor, betacellulin precursor, heparin binding EGF-like growth factor, epiregulin, HUS 19878, myxomavirus growth factor (MGF), Shope fibroma virus growth factor (SFGF), and schwannoma derived growth factor.
32. The method of claim 23, wherein the gastrointestinal mucositis results from cytotoxic or immune-suppressing therapy.

33. The method of claim 23, wherein the mucositis results from ARC or AIDS.
34. The method of claim 23, wherein the subject is a mammal.
35. The method of claim 34, wherein the mammal is a human.
36. A method for expansion of a precursor cell comprising contacting the cell *in vitro* with an amount of a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a functional fragment thereof, or a mimetic thereof effective to promote precursor cell proliferation, and culturing the cell *in vitro* under growth conditions such that the cell proliferates.
37. The method of claim 36, wherein the precursor cell is of ectodermal origin.
38. The method of claim 36, wherein the precursor cell is of endodermal origin.
39. The method of claim 36, wherein the precursor cell is of mesodermal origin.
40. The method of claim 36, wherein the precursor cell is selected from the group consisting of hematopoietic precursor cells, epithelial precursor cells, kidney precursor cells, neural precursor cells, skin precursor cells, osteoblast precursor cells, chondrocyte precursor cells, and liver precursor cells.
41. The method of claim 36, wherein the TGF- $\alpha$  polypeptide has a sequence as set forth in SEQ ID NO:1.


42. The method of claim 36, wherein the TGF- $\alpha$  polypeptide has a sequence NH<sub>2</sub>- X<sub>1a</sub> - Cys - His - Ser - X<sub>1b</sub> - X<sub>2</sub> - X<sub>1a</sub> - X<sub>1b</sub> - X<sub>1a</sub> - X<sub>3</sub> - Cys - COOH (SEQ ID NO:4) wherein X<sub>1a</sub> and X<sub>1b</sub> are independently Val, Gly or Ala; X<sub>2</sub> is Tyr or Phe; X<sub>3</sub> is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional fragment having TGF- $\alpha$  activity.
43. The method of claim 42, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X<sub>4</sub> - His - X<sub>1c</sub> - X<sub>4</sub> - X<sub>5</sub> - X<sub>6</sub> - X<sub>1c</sub> (SEQ ID NO:5) wherein X<sub>4</sub> is Glu or Asp; X<sub>5</sub> is Leu or Ile; and X<sub>6</sub> is Asp or Glu.
44. The method of claim 43, wherein X<sub>1a</sub> is Val, X<sub>1b</sub> is Gly and X<sub>1c</sub> is Ala.
45. The method of claim 43, wherein X<sub>2</sub> is Tyr and X<sub>3</sub> is Arg.
46. The method of claim 43, wherein the functional fragment is 18 amino acids in length and X<sub>1a</sub> is Val, X<sub>1b</sub> is Gly, X<sub>1c</sub> is Ala and X<sub>4</sub> is Gly.
47. The method of claim 36, wherein the TGF- $\alpha$  polypeptide has a sequence as set forth in SEQ ID NO:3.
48. The method of claim 36, wherein the TGF- $\alpha$  related polypeptide is selected from the group consisting of vaccinia growth factor, amphiregulin precursor, betacellulin precursor, heparin binding EGF-like growth factor, epiregulin, HUS 19878, myxomavirus growth factor (MGF), Shope fibroma virus growth factor (SFGF), and schwannoma derived growth factor.

49. The method of claim 36, wherein the precursor cell is a hematopoietic stem cell.
50. The method of claim 36, wherein the precursor cell contains a recombinant nucleic acid encoding a protein of value in the treatment of a human disease or disorder.
51. The method of claim 36, wherein the contacting is carried out by a method comprising exposing the precursor cell to cells recombinantly expressing the TGF- $\alpha$  polypeptide, functional fragment thereof, or a mimetic thereof.
52. The method of claim 36, wherein the contacting is carried out by culturing the precursor cell in medium containing a substantially pure TGF- $\alpha$  polypeptide, functional fragment thereof, or a mimetic thereof.
53. The method of claim 36, wherein substantially no differentiation of the precursor cell occurs.
54. The method of claim 36, wherein the precursor cells are in a mixed population of cells.
55. The method of claim 36, wherein the precursor cells are substantially enriched.
56. A method for expansion of a precursor cell population comprising recombinantly expressing within the cell an amount of a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a functional fragment thereof, or a mimetic thereof effective to induce proliferation of the cells; and culturing the cells under conditions such that the cell proliferates, thereby expanding the cell population.

57. A method for expansion of a hematopoietic precursor cell population comprising recombinantly expressing within the cell an amount of a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a functional fragment thereof, or a mimetic thereof effective to induce proliferation of the cells; and culturing the cells under conditions such that the cell proliferates, thereby expanding the cell population.
58. A method for expansion of an epithelial precursor cell population comprising recombinantly expressing within the cell an amount of a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a functional fragment thereof, or a mimetic thereof effective to induce proliferation of the cells; and culturing the cells under conditions such that the cell proliferates, thereby expanding the cell population.
59. A method for expansion of a liver precursor cell population comprising recombinantly expressing within the cell an amount of a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a functional fragment thereof, or a mimetic thereof effective to induce proliferation of the cells; and culturing the cells under conditions such that the cell proliferates, thereby expanding the cell population.
60. A method for expansion of a human precursor cell population comprising contacting the precursor cell *in vitro* with a second cell wherein the second cell recombinantly expresses a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a functional fragment thereof, or a mimetic thereof effective to induce proliferation of the cells; and culturing the cells under conditions such that the cell proliferates, thereby expanding the cell population.

61. A method for inducing proliferation of mammalian neuronal cells comprising contacting a mammalian neuron *in vitro* with a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a functional fragment thereof, or a mimetic thereof effective to induce proliferation of the cells; and culturing the cells under conditions such that the cell proliferates.
62. A method for expanding stem cells *ex vivo*, comprising:  
(a) culturing stem cells from a subject;  
(b) contacting the stem cell culture with a TGF- $\alpha$  polypeptide, a TGF- $\alpha$  related polypeptide, a functional fragment thereof, or a mimetic thereof in an amount necessary to expand the stem cells.
63. The method of claim 62, wherein the TGF- $\alpha$  polypeptide has a sequence as set forth in SEQ ID NO:1.
64. The method of claim 62, wherein the TGF- $\alpha$  polypeptide has a sequence NH<sub>2</sub>- X<sub>1a</sub> - Cys - His - Ser - X<sub>1b</sub> - X<sub>2</sub> - X<sub>1a</sub> - X<sub>1b</sub> - X<sub>1a</sub> - X<sub>3</sub> - Cys - COOH (SEQ ID NO:4) wherein X<sub>1a</sub> and X<sub>1b</sub> are independently Val, Gly or Ala; X<sub>2</sub> is Tyr or Phe; X<sub>3</sub> is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional fragment having TGF- $\alpha$  activity.
65. The method of claim 64, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4:  
- X<sub>4</sub> - His - X<sub>1c</sub> - X<sub>4</sub> - X<sub>5</sub> - X<sub>6</sub> - X<sub>1c</sub> (SEQ ID NO:5) wherein X<sub>4</sub> is Glu or Asp; X<sub>5</sub> is Leu or Ile; and X<sub>6</sub> is Asp or Glu.
66. The method of claim 64, wherein X<sub>1a</sub> is Val, X<sub>1b</sub> is Gly and X<sub>1c</sub> is Ala.
67. The method of claim 65, wherein X<sub>2</sub> is Tyr and X<sub>3</sub> is Arg.

68. The method of claim 65, wherein the functional fragment is 18 amino acids in length and  $X_{1a}$  is Val,  $X_{1b}$  is Gly,  $X_{1c}$  is Ala and  $X_4$  is Gly.
69. The method of claim 62, wherein the TGF- $\alpha$  polypeptide has a sequence as set forth in SEQ ID NO:3.
70. The method of claim 62, wherein the TGF- $\alpha$  related polypeptide is selected from the group consisting of vaccinia growth factor, amphiregulin precursor, betacellulin precursor, heparin binding EGF-like growth factor, epiregulin, HUS 19878, myxomavirus growth factor (MGF), Shope fibroma virus growth factor (SFGF), and schwannoma derived growth factor.
71. A method for treating Type I or Type II diabetes by expanding a subject's population of insulin-producing cells, comprising administering an effective amount of a TGF- $\alpha$  polypeptide (SEQ ID NO:1), a TGF- $\alpha$  related polypeptide, a TGF- $\alpha$ 57 polypeptide (SEQ ID NO:3), a fragment thereof, or a mimetic thereof.
72. A method for treating AIDS and HIV infection by increasing a subject's population of CD4+ T cells, comprising administering an effective amount of a TGF- $\alpha$  polypeptide (SEQ ID NO:1), a TGF- $\alpha$  related polypeptide, a TGF- $\alpha$ 57 polypeptide (SEQ ID NO:3), a fragment thereof, or a mimetic thereof.



TGFα

FIG. 1




FIG. 2






FIG. 3






FIG. 4

**FIG. 5****FIG. 6**

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number  
**WO 01/12127 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 38/00**,  
C07K 1/00

(74) Agent: **HAILE, Lisa, A.**; Gray Cary Ware & Friedenrich  
LLP, 4365 Executive Drive, Suite 1600, San Diego, CA  
92121-2189 (US).

(21) International Application Number: PCT/US00/22882

(22) International Filing Date: 17 August 2000 (17.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/378,567 19 August 1999 (19.08.1999) US  
09/459,813 13 December 1999 (13.12.1999) US  
09/492,935 27 January 2000 (27.01.2000) US  
09/559,248 26 April 2000 (26.04.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: **STEM CELL PHARMACEUTICALS, INC.** [US/US]; 562 First Avenue South, Suite 700, Seattle, WA 98104 (US).

**Published:**  
— with international search report

(72) Inventors: **TWARDZIK, Daniel, R.**; 10195 Southbeach Drive, Bainbridge Island, WA 98110 (US). **PERNET, Andre**; 1221 S. Estate Lane, Lake Forest, IL 60045 (US). **FELKER, Thomas, S.**; 11344 S.W. Mc Cormick Place, Vashon, WA 98070 (US). **PASKELL, Stefan**; 6075 N.E. Tolo Road, Bainbridge Island, WA 98110 (US).

(88) Date of publication of the international search report:  
30 August 2001

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: TGF- $\alpha$  POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR

(57) Abstract: Disclosed are TGF- $\alpha$  polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include *ex vivo* and *in vivo* applications.



WO 01/12127 A3

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/22882

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC(7) : A61K 38/00; C07K 1/00 US CL : 514/2; 530/300, 351 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/2; 530/300, 351		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) USPATFULL, MEDLINE, WPIDS		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95/24466 A1 (HUMAN GENOME SCIENCES, INC.) 14 September 1995, see entire document.	1-35
Y	WO 96/21676 A1 (THE SECRETARY OF STATE FOR DEFENCE) 18 July 1996, see entire document.	1-35
Y	WO 97/25349 A1 (HUMAN GENOME SCIENCES, INC.) 17 July 1997, see entire document.	1-35
Y	US 5,690,928 A (HEIMBROOK et al.) 25 November 1997, see entire document.	1-35
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 28 FEBRUARY 2001	Date of mailing of the international search report 13 MAR 2001	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer Jeffrey S. Parkin, Ph.D. Telephone No. (703) 308-1235	

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/22882

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-35

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/22882

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-35, drawn to *in vitro* and *in vivo* methods of treating or repairing tissues through the administration of TGF- $\alpha$  polypeptides.

Group II, claim(s) 36-60, drawn to *in vitro* and *in vivo* methods of expanding cell populations.

Group III, claim(s) 61, drawn to an *in vitro* method for the induction of neuronal cells through the administration of TGF- $\alpha$  polypeptides.

Group IV, claim(s) 62-70, drawn to *ex vivo* methods of cell expansion through the administration of TGF- $\alpha$  polypeptides.

Group V, claim(s) 71, drawn to a method of treating Type I or II diabetes through the administration of TGF- $\alpha$  polypeptides.

Group VI, claim(s) 72, drawn to a method of treating HIV infection and AIDS through the administration of TGF- $\alpha$  polypeptides.

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The aforementioned groups are each directed toward disparate methods of use (i.e., treating mucositis, expanding cell precursors, inducing the proliferation of neuronal cells, the *ex vivo* expansion of stem cells, the treatment of diabetes, the treatment of AIDS) and employ different scientific reagents, methodology steps, and accomplish different scientific objectives (i.e., cell expansion, the treatment of specific clinical disorders). Accordingly, the designated groups lack a special technical feature.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number  
**WO 01/12127 A3**

- (51) International Patent Classification<sup>7</sup>: **A61K 38/00**, C07K 1/00
- (21) International Application Number: PCT/US00/22882
- (22) International Filing Date: 17 August 2000 (17.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/378,567 19 August 1999 (19.08.1999) US  
09/459,813 13 December 1999 (13.12.1999) US  
09/492,935 27 January 2000 (27.01.2000) US  
09/559,248 26 April 2000 (26.04.2000) US
- (71) Applicant: **STEM CELL PHARMACEUTICALS, INC.** [US/US]; 562 First Avenue South, Suite 700, Seattle, WA 98104 (US).
- (72) Inventors: **TWARDZIK, Daniel, R.**; 10195 Southbeach Drive, Bainbridge Island, WA 98110 (US). **PERNET, Andre**; 1221 S. Estate Lane, Lake Forest, IL 60045 (US). **FELKER, Thomas, S.**; 11344 S.W. Mc Cormick Place, Vashon, WA 98070 (US). **PASKELL, Stefan**; 6075 N.E. Tolo Road, Bainbridge Island, WA 98110 (US).
- (74) Agent: **HAILE, Lisa, A.**; Gray Cary Ware & Friedenrich LLP, 4365 Executive Drive, Suite 1600, San Diego, CA 92121-2189 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report  
— with amended claims
- (88) Date of publication of the international search report: 30 August 2001
- Date of publication of the amended claims: 27 September 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TGF- $\alpha$  POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR

(57) Abstract: Disclosed are TGF- $\alpha$  polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include *ex vivo* and *in vivo* applications.



WO 01/12127 A3



## AMENDED CLAIMS

[received by the International Bureau on 11 May 2001 (11.05.01);  
new claims 73-75 added; remaining claims unchanged (1 page)]

73. A composition, comprising a compound selected from the group consisting of formula I, formula II, formula III, formula IV, or formula V, wherein formula I is: -



wherein  $R_1$  is  $-NH_2$ ;  $R_1$  is  $R_3 - X_3$ , wherein  $R_3$  is a polyethylene glycol (PEG) with molecular weight of from about 2000 daltons to about 10,000 daltons, attached to the free  $NH_2$  moiety of  $X_3$ , wherein  $X_3$  is Lys or Arg or one or more of the following seven amino acids from formula IV:



(IV)

wherein  $X_{1a}$  is independently Val, Gly or Ala and  $X_3$  is Lys or Arg;

wherein T is the native sequence of human  $TGF\alpha$  (SEQ ID NO:1) from amino acid residue 8 (Cys) to amino acid residue 44 (Cys) consisting of native L amino acids; and

wherein  $R_2$  is  $-COOH$  or one or more of the following seven amino acids from formula V:



wherein  $X_4$  is Glu or Asp, wherein  $X_5$  is Leu or Ile, wherein  $X_6$  is Asp or Glu, and wherein  $X_1$  is independently Val, Gly or Ala.

74. A  $TGF-\alpha$  polypeptide having the sequence of formula VI, wherein formula VI is:



wherein human  $TGF\alpha$  is a 50 amino acid polypeptide having a sequence as set forth in SEQ ID NO:1.

75. The  $TGF-\alpha$  polypeptide of claim 74, wherein polyethylene glycol (PEG) is attached to the  $TGF-\alpha$  at amino acid Arg 42, Val 1, Arg 22, Lys 29, or any combination thereof.